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ABSTRACT 
Tenofovir (TFV) is a reverse transcriptase inhibitor that is approved by the United States Food 
and Drug Administration (FDA) to treat HIV and chronic Hepatitis B.  It has a long half-life, 
allowing for once a day dosing and is effective in treatment of both naive and experienced 
patients.  It is administered orally as tenofovir disoproxil fumarate (TDF) and is deesterified in 
plasma to the active drug TFV.  However, renal impairment is associated with its use; TFV can 
induce decreased glomerular filtration rate (GFR) and free calcitriol, renal failure, and Fanconi 
Syndrome.  The exact mechanism of toxicity currently remains unknown, largely due to limited 
experimental models.  The purpose of this study was to investigate the mechanisms of 
cytotoxicity and oxidative damage observed in HK-2 cells following treatment with TFV and to 
determine if managing oxidative damage mitigates toxicity.  TFV is the active form of TDF and 
was used for all studies.  HK-2 cells were grown to confluency for 48 h and then exposed to 0-
28.8 µM TFV for 24, 48, or 72 h.  The vehicle used for all studies was phosphate buffered saline 
(PBS).  TFV induces a loss of cell viability compared to the control within 24 h as shown by an 
MTT assay, Trypan Blue Exclusion cell counts, and lactate dehydrogenase (LDH) leakage.  
Oxidative stress and mitochondrial damage were assessed in whole cell lysate and different cell 
fractions using OxyBlot and western blot for 4-hydroxynonenol (4-HNE), tumor necrosis factor 
alpha (TNFα), caspase 3, 8, and 9, MnSOD, ATP Synthase, and cytochrome c and showed an 
increase in protein carbonylation and loss of mitochondrial membrane integrity following 72 h 
exposure to 28.8 µM TFV.  TFV induces apoptosis at 72 h exposure as shown by western blot 
analysis of cytochrome c leakage and activation of caspase 3 and 9.  Studies conducted using 
Seahorse XFp technology determined that TFV alters mitochondrial function.  Studies were 
conducted using a 1 h pretreatment with antioxidants resveratrol, N-acetyl-L-cysteine, or 
xiv 
ascorbic acid, and results showed protection of cell viability following 24 h exposure to 3 and 
14.5 μM TFV.  These studies suggest that mitochondrial damage and oxidative stress occur in 
HK-2 cells treated with TFV and that controlling oxidative damage may help prevent toxicity 
from developing.  Additional knowledge of subcellular events associated with tenofovir 
nephrotoxicity can be used to develop clinical methods to mitigate toxicity. 
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Abstract 
 Over one million people in the United States are living with Human Immunodeficiency 
Virus (HIV) which may progress to Acquired Immunodeficiency Syndrome (AIDS). The use of 
antiviral therapy has successfully controlled the rate of viral growth in patients. Antiviral agents 
improve the quality of life and reduce the potential for spreading HIV; HIV is currently 
considered a chronic disease provided patients are compliant with their antiviral medications. 
Tenofovir is a nucleoside transcriptase inhibitor that prevents viral replication and is approved 
for treatment of HIV and chronic hepatitis B infection.  Tenofovir is an antiretroviral drug used 
alone and in combination with other nucleoside reverse transcriptase inhibitor agents to lower 
viral load in HIV patients. Tenofovir is administered as a prodrug in order to increase 
bioavailability.  The prodrug forms of tenofovir are tenofovir disoproxil fumarate approved in 
2001 and tenofovir alafenamide approved in 2016. Tenofovir is extensively used in controlling 
HIV as it is administered once daily allowing for good compliance. This minireview discusses 
the changes in dosing that are needed in the presence of renal impairment which is a common 
occurrence with HIV chronic disease progression. The impact of food, age, and drug transporters 
on tenofovir absorption and clearance will be discussed. The potential special conditions 
occurring with fixed combination doses containing tenofovir will also be reviewed, including the 
use of cobicistat, a cytochrome P450 inhibitor. The short review also addresses some newer 
preparations using niosomes to improve tenofovir absorption and delivery to the target cells. 
Introduction 
Human Immunodeficiency Virus (HIV) is a virus that decimates the immune system. 
HIV targets a specific type of white blood cells known as T-cells, T-lymphocytes or CD4 cells. 
A decline in CD4 cell count mediated by HIV leaves the body open to opportunistic infections.  
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At one time, HIV rapidly progressed to Acquired Immunodeficiency Syndrome (AIDS) and 
death, but advancements in highly active antiretroviral therapy (HAART) have made HIV a 
chronic condition rather than a death sentence.  Tenofovir (TFV), formerly known as PMPA [9-
(R)-(2-phosphonomethoxypropyl) adenine] is a reverse transcriptase inhibitor that has potent and 
selective inhibition of HIV and herpes viruses’ reverse transcriptase.  TFV is an acyclic 
nucleotide analogue of adenosine 5’ monophosphate that is phosphorylated intracellularly by 
adenylate kinase to its active form, tenofovir diphosphate.  TFV is effective in cases of 
nucleoside resistant HIV infection, making it a first line agent for treatment of this disease 
(Miller, Margot, Hertogs, Larder, & Miller, 2001; Squires et al., 2003).   
Despite its efficacy, poor bioavailability was a limiting factor in development of TFV as 
a clinical agent.  Oral administration of TFV had 18% bioavailability in beagles and 5.3% in 
monkeys (Cundy et al., 1998; Shaw et al., 1997).  Research efforts subsequently focused to 
improve bioavailability by altering TFV formulation but maintaining antiviral activity. Two 
methyl carbonate esters were added to form the prodrug tenofovir disoproxil fumarate (TDF), 
which demonstrated equivalent antiviral activity with bioavailability increased to 30.1% in 
beagles and 25% in humans (Barditch-Crovo et al., 2001; Shaw et al., 1997).  TDF was approved 
in Fall 2001 by the United States Food and Drug Administration (FDA) to treat chronic Hepatitis 
B and HIV in conjunction with other agents (Gilead Sciences, 2001).  There are several factors 
that alter TDF bioavailability and pharmacokinetics, including age, sex, and food intake.  This 
article provides a review of tenofovir bioavailability as well as factors that have an impact on 
TFV pharmacokinetics in human and animal models.   
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Pharmacokinetics and Bioavailability of Tenofovir Disoproxil Fumarate 
 TDF is formulated into a  tablet for oral administration with a standard dose of 300 mg.  
TDF has a higher lipophilicity than TFV. The LogP, a measure of the partition coefficient 
between octanol and water, is 2.1 for TDF compared to -1.6 for TFV. The higher partition 
coefficient would  enable increased intestinal drug absorption.  As a result of higher lipophilicity, 
TDF has an oral bioavailability of 25% in HIV-1 infected patients (Barditch-Crovo et al., 2001). 
Following absorption, TDF is cleaved in the plasma by esterases (Figure 2) first to a monoester 
intermediate, and then to TFV (Choi, Bui, & Ho, 2008; Shaw et al., 1997).  This hydrolysis is 
effective enough that TDF is not observed in systemic plasma samples.   
 
 
 
 
 
 
 
 
Figure 1.   Structure of deoxyadenosine 5’ triphosphate (A) and tenofovir diphosphate (B) 
After intestinal absorption and plasma hydrolysis, TFV is phosphorylated intracellularly 
by adenylate kinase to its active form, tenofovir diphosphate (TDP) (Figure 3).  As a nucleotide 
analogue, TFV diphosphate competes with deoxyadenosine 5’ triphosphate (Figure 1) for 
incorporation into the growing DNA strand during HIV transcription and blocks the activity of 
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reverse transcriptase, leading to elongation termination (Balzarini et al., 1993; Robbins, Srinivas, 
Kim, Bischofberger, & Fridland, 1998).     
 
 
 
 
 
Figure 2. Conversion of tenofovir disoproxil fumarate to tenofovir by intestinal and plasma 
esterases. 
 
Intravenous administration of 1 mg/kg TDF has a steady state volume of distribution of 
813 mL/kg, indicating that tissue distribution is extensive and exceeds total body water.  Cmax of 
the same intravenous dose is approximately 2.7 μg/ml, and TFV serum concentration decreases 
in a biphasic manner (Deeks et al., 1998).  The measured area under the curve (AUC) was 3.024 
μg ∙h/mL.  The oral bioavailability of TDF was calculated by comparing the AUC for a 300 mg 
oral dose to the AUC for a 1 mg/kg intravenous dose; oral TDF has 25% bioavailability when 
compared to an intravenous dose (Barditch-Crovo et al., 2001). 
Figure 3.  Intracellular activation of tenofovir to tenofovir diphosphate by adenylate kinase 
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The half-life for a single intravenous TDF injection was 7 h compared to 12 h for a single 
oral dose of 300 mg TDF (Barditch-Crovo et al., 2001; Deeks et al., 1998; Hawkins et al., 2005). 
The intracellular half-life of TDF is estimated to be 12-50 h (Robbins et al., 1998).   
The pharmacologic antiviral activity of TDF and ultimately TFV is proportional to the 
intracellular concentration in target cells. A single oral dose of TDF to macaques provided 
almost 8 fold higher intracellular levels of the active TFV-diphosphate compared to a single sub-
cutaneous injection of TFV (Durand-Gasselin et al., 2009). Additionally, oral TDF shows greater 
accumulation in peripheral blood mononuclear cells (PBMCs) when given as an oral prodrug 
rather than a subcutaneous injection of TFV to macaques (Durand-Gasselin et al., 2009).   The 
bioavailability in macaques was 31%, which was similar to humans (Barditch-Crovo et al., 
2001). These findings suggest that TDF first enhanced bioavailability, but also provided 
improved delivery to the target cells.  The excellent uptake into cells allows for once daily 
dosing. Once daily dosing increases compliance, which will promote therapeutic success, which 
is important in controlling HIV as a chronic disease.    
In general, differences in TDF pharmacokinetics are not apparent when comparing oral 
and intravenous routes of administration. Oral TDF has equivalent pharmacokinetics to 
intravenous TDF.  Once Cmax is reached, serum TFV concentrations decline in a biphasic 
manner.  TFV is excreted 92% unchanged by the kidney and 4.5% unchanged in feces.  Renal 
TFV clearance exceeds calculated creatinine clearances, indicating that TFV is actively secreted 
by the kidneys (Barditch-Crovo et al., 2001; Cundy et al., 1998; Durand-Gasselin et al., 2009).  
In vitro transport studies indicate that TFV is a substrate for the multidrug resistance-associated 
protein 4 (MRP4), an apical membrane efflux transporter (A. S. Ray et al., 2006). TFV was not a 
substrate for MRP2. These in vitro studies would suggest that active tubular secretion of TFV 
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into the nephron lumen is mediated by MRP4.  It is worth noting that while TFV is not a 
substrate of MRP1, MRP2, or MRP 3, at concentrations exceeding 50 μM, TFV does inhibit 
these transporters in Madin-Darby canine kidney II (MDCKII) cells (Weiss, Theile, Ketabi-
Kiyanvash, Lindenmaier, & Haefeli, 2007).    
Pharmacokinetics and Bioavailability of TDF in Patients with Renal Insufficiency 
  TDF pharmacokinetics and bioavailability differ in patients with renal insufficiency, 
which is an important consideration in individuals with HIV.  The frequency of acute kidney 
injury is more common in HIV infected individuals and can progress to end stage renal disease.  
In 2005, it was estimated that in the United States, almost 3,000 people had end stage renal 
disease related to HIV.  A decline in renal function is a frequent occurrence in HIV disease 
progression (Schwartz & Klotman, 1998; Wyatt et al., 2009).  HIV-associated nephropathy 
(HIVAN) primarily affects the glomerulus, and is characterized by proteinuria, elevated serum 
creatinine and blood urea nitrogen (BUN), focal segmental glomerulosclerosis (FSGS), and 
microcystic tubular dilation. Renal lesions lead to the collapse of the glomeruli and rapid 
progression to kidney failure (Laurinavicius, Hurwitz, & Rennke, 1999; P. E. Ray, 2012).  
While HIVAN occurs less frequently in patients whose HIV is well controlled with 
antiretroviral therapy (ART) (Fabian, Naicker, Goetsch, & Venter, 2013), renal insufficiency 
should be considered when using TDF.  In a study conducted in patients with varying degrees of 
renal insufficiency, patients with moderate and severe renal impairment (noted as creatinine 
clearance (CLCR) of 30-49ml/min and <30ml/min, respectively) had an AUC 2-6 fold higher than 
in patients with normal renal function.  The increase in AUC was most likely due to a decrease in 
TFV clearance that was directly proportional to the observed decreases in CLCR (Kearney, 
Flaherty, & Shah, 2004).   
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Patients treated with TDF do have an increased incidence of renal impairment, and there 
is a positive correlation between increased TFV serum concentrations, duration of treatment with 
TDF, and incidence of renal toxicity (Ezinga, Wetzels, Bosch, van der Ven, and Burger, 2014; 
Fux et al., 2007; Quesada et al., 2015; Verhelst et al., 2002).  TDF is associated with increased 
serum creatinine and plasma vitamin D binding, decreased free calcitriol levels and glomerular 
filtration rate (GFR), renal failure, and Fanconi Syndrome (Del Palacio, Romero, & Casado, 
2012; Hall, Hendry, Nitsch, & Connolly, 2011; Havens et al., 2013).  Fanconi syndrome is a 
disorder of renal tubular function characterized by excess renal excretion of potassium, 
phosphate salts, protein, urate, and glucose. Clinical studies indicate that the mitochondria of the 
proximal tubules are the target of TFV induced toxicity as shown by enlarged and malformed 
mitochondria in electron microscopy cross sections (Cote et al., 2006; Hall et al., 2011; Herlitz et 
al., 2010; Woodward et al., 2009).  Proximal tubular mitochondrial toxicity has also been 
described in mice and rats treated with TFV as shown by disruptions in mitochondrial cristae and 
a reduction in mitochondrial DNA (mtDNA) levels (Kohler et al., 2009; Lebrecht et al., 2009).   
Changes in TDF administration are recommended for patients with decreased renal 
function to reduce plasma concentrations and to prevent worsening of renal damage.  In patients 
with moderate impairment (CLCR 30-49ml/min), 300 mg dose of TDF should be reduced in 
frequency to once every 48 h instead of once daily.  In patients with severe impairment (CLCR 
10-29ml/min) or those who are on  hemodialysis, the 300 mg dose should be administered every 
72-96 h or once every 7 days, respectively (Gilead Sciences, 2001). 
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Pharmacokinetics and Bioavailability of TDF in Fixed Dose Combination Tablets 
To simplify HIV treatment regimens and increase compliance, TDF is commonly paired 
with other antiretrovirals in single dose combination tablets.  The drugs currently combined with 
TDF in fixed dose combinations are: emtricitabine (FTC, 200 mg), efavirenz (EFV, 600 mg), 
rilpivirine (RPV, 25 mg), the integrase strand transfers inhibitor elvitegravir (EVG, 150 mg) and 
the CYP 3A4 inhibitor cobicistat (COBI, 150 mg). The most common formulations are: 
TDF/FTC, TDF/FTC/EFV, TDF/FTC/RPV and TDF/FTC/EVG/COBI.  Each formulation 
includes TDF as a standard 300 mg dose.  Bioequivalence is evaluated in combination tablet 
formulations by maintenance of pharmacokinetic parameters Cmax, AUC, and t1/2 within a 
confidence interval (CI) of 80-125% of the reference formulation.   
The first fixed dose combination approved by the FDA for treatment of HIV contained 
TDF/FTC/EFV.  FTC, EFV and TDF all have half-lives that are suitable for once a day dosing 
(FTC, 39h; EFV, 23 h; TDF, 15-60 h) (Barditch-Crovo et al., 2001; DiCenzo et al., 2003; 
Hawkins et al., 2005; Saag, 2006).  When studied as a fixed-dose combination tablet, all 
pharmacokinetic parameters had geometric mean ratios close to 100% and 90% CI within the 
bioequivalence bounds of individual formulations, indicating that TDF, EFV, and FTC can be 
combined into a once daily combination tablet (Mathias et al., 2007).  The combination of 
TDF/FTC/EFV is FDA approved as a complete regimen for HIV treatment and can also be used 
in combination with other HIV medications (Gilead Sciences, 2006).   
TDF/FTC/RPV combination provides two nucleos(t)ide reverse transcriptase inhibitors 
(TDF/FTC) with a non-nucleoside reverse transcriptase inhibitor, RPV to treat HIV.  Initial 
studies showed that addition of 25mg RPV to a TDF/FTC treatment regimen showed 
equivalence in HIV suppression when compared to TDF/FTC + EFV regimens and had less 
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adverse effects than EFV (Cohen et al., 2011; Molina et al., 2011).  RPV has a t1/2 of 
approximately 50 h, making it a suitable candidate for inclusion in a once daily combination 
tablet (Cohen et al., 2013).  In a bioequivalence study, all pharmacokinetic parameters of a 
TDF/FTC/RPV single dose tablet demonstrated a 90% CI within the bioequivalence bounds of 
individual formulations, indicating that TDF, FTC, and RPV can be combined into a once daily 
combination tablet.  While both TDF and FTC are approved to be taken with or without a meal, 
RPV bioavailability is reduced 40% in a fasted state alone and in a combination tablet. 
Therefore, TDF/FTC/RPV should be taken with  food (Mathias et al., 2012).   
TDF/FTC combination tablets also demonstrate bioequivalence for all tested 
pharmacokinetic parameters when compared to individual therapy (Blum, Chittick, Begley, & 
Zong, 2007).  TDF/FTC is FDA approved to treat HIV-1 in conjunction with other therapies, but 
is not considered a complete regimen.  TDF/FTC is also FDA-approved for use in pre-exposure 
prophylaxis (PrEP) therapy to prevent the transmission of HIV-1 between sexual partners 
(Anderson et al., 2012; Baeten et al., 2012; Grant et al., 2010).  The use of TFV-containing 
regimens for PrEP is discussed in further detail in the “Tenofovir as a Prophylactic Agent” 
section below.   
Recently COBI has been included in HAART to treat HIV.  While it has no antiviral 
activity on its own, COBI is a pharmacoenhancer for drugs that are metabolized by cytochrome 
P450 3A enzymes (CYP3A).  COBI is a potent CYP3A inhibitor, and is commonly used with 
protease and integrase inhibitors such as EVG in the treatment of HIV.  In a fixed dose 
combination study, administration of COBI/TDF/EVG combination tablets showed 
bioequivalence; however, TDF Cmax was increased 30% but AUC was largely unaffected 
(German, Warren, West, Hui, & Kearney, 2010).  COBI may alter the half-life of other drugs 
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taken concurrently that are biotransformed by CYP3A as inhibition by COBI may slow 
biotransformation by CYP3A. COBI is a substrate for CYP3A and treatment with agents that 
induce or inhibit CYP3A has the potential to alter the effects of COBI (Sherman, Worley, Unger, 
Gauthier, & Schafer, 2015).  
 This increase in Cmax may be due to COBI’s transient inhibition of P-glycoprotein efflux 
transporter (Pgp); TFV is a recognized substrate of the Pgp  transporter (German et al., 2010; 
Lepist et al., 2012).  It is worth noting that COBI inhibition of P-glycoprotein is weak, much like 
other protease inhibitors such as ritonavir (RTV); COBI, RTV, and other protease inhibitors do 
not inhibit efflux transporters at pharmacologically relevant concentrations in systemic 
circulation (Cihlar et al., 2007; Polli et al., 1999; Ray et al., 2006; van der Sandt et al., 2001; 
Washington, Duran, Man, Sikic, & Blaschke, 1998) but may reach concentrations high enough to 
inhibit efflux transporters in the gut (Ray et al., 2006; Tong et al., 2007).   
Effect of Food Intake on TDF Bioavailability 
 Taking TDF with food has shown to improve bioavailability.  However, it does not 
appear that the type of meal matters, as no changes in pharmacokinetic parameters are seen with 
administration of a standard meal, high fat meal, or protein-rich meal.  In a study of healthy 
Japanese males, participants ingested a standard meal (11.4g protein, 9.6g fat, and 72.2g 
carbohydrates) or a protein-rich drink (8.8g protein, 8.8g fat, 34.3g carbohydrates) prior to 
administration of a 300 mg dose of TDF.  There was a 28% decrease in both AUC and Cmax when 
TDF was administered in a fasted state compared to administration following a standard meal or 
a protein-rich drink.  Although Cmax
 
was slightly lower in the protein-drink group (554 ng/ml vs. 
613 ng/ml), AUC and t1/2 were not different between meals, indicating that a standard meal and a 
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protein-rich drink produce bioequivalent increases in TDF bioavailability over fasted 
administration (Shiomi et al., 2014).   
 Bioavailability of TDF was increased in one study using a very high fat meal in  HIV 
uninfected males. Effects of a very high fat meal were evaluated during phase I testing of TDF.  
Participants ingested a high fat meal (50% fat, 1000kcal) 30 minutes prior to administration of 
TDF.  TDF bioavailability in the fed group was increased 40% over the fasted group, and Cmax 
was increased 14%.  Tmax also increased from 0.5-1 h in a fasted state to 1.3-3 h in a fed state, 
consistent with a slowing of gastric emptying following a meal (Barditch-Crovo et al., 2001; 
Kearney et al., 2004).  This same group noted that a high fat meal was not indicative of normal 
diet, and studied the effects of a light meal on TDF bioavailability and found no significant 
effect.  According to its prescribing information, TDF can be administered with or without a 
meal (Gilead Sciences, 2001).  It should be noted that certain TDF fixed-dose combination 
formulations such as TDF/FTC/RPV and TDF/FTC/ EVG/COBI should be taken with food due 
to significant decreases in RPV (40%) and EVG (50%) bioavailability in a fasted state (German 
et al., 2010; Mathias et al., 2012; Shiomi et al., 2014). 
 Though TDF is intended to be cleaved by plasma esterases, it is susceptible to cleavage 
by intestinal carboxylesterases when administered by the oral route.  It is hypothesized that this 
intestinal hydrolysis and efflux via Pgp is what limits TDF bioavailability in humans (Shaw et 
al., 1997; van Gelder et al., 2002; Yuan, Dahl, & Oliyai, 2001).  Ester rich fruit juices such as 
grapefruit, orange, cranberry, and concord grape have been shown to increase oral absorption of 
drugs such as lopinavir (LPV) and saquinavir (SQV) through inhibition of Pgp, MRP-2, and 
various cytochrome P450s (CYPs) (Bailey, Malcolm, Arnold, & Spence, 1998; Honda et al., 
2004; Ravi, Joseph, Avula, & Anthireddy, 2015).  As TDF is a substrate of Pgp, studies were 
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conducted to determine if ester rich fruit juices increase TDF bioavailability and intestinal 
absorption.  Strawberry juice extract increased TDF intestinal absorption in Caco-2 cell lines to 
67%, while grapefruit and cranberry juice extracts increased TDF bioavailability by 97 and 24% 
in an in vivo rat study (Shailender, Ravi, Saha, & Myneni, 2017; Van Gelder et al., 1999).  
Additional investigation needs to be done to determine if this effect is also seen in humans.          
Age Related Differences in Tenofovir Bioavailability and Pharmacokinetics 
TDF is FDA approved for use in the US in children age two and older.  As HIV is a 
chronic disease, it is important to determine the developmentally associated changes in 
pharmacokinetic parameters of antiretroviral therapy.  Studies have been conducted to determine 
the pharmacokinetic profile of TDF administration in neonates, children/adolescents, and adults.  
TDF pharmacokinetics vary in children comparatively to adults, and these variables need to be 
considered when determining dosing.  Initial pharmacokinetic studies were run following TDF’s 
approval for use in adults.  Hazra and colleagues (2004) determined the adult-equivalent dose in 
children to be ~175 mg/m
2
 based on calculations from initial pharmacokinetic studies in adults.  
In a cohort of children ranging from 4-18 years of age given 175 mg TDF for four weeks, AUC 
and Cmax were reported to be 34 and 27% lower than the equivalent dose in adults.  The decrease 
in AUC may be explained by the observed 1.5 times faster clearance in children (Barditch-Crovo 
et al., 2001; Hazra et al., 2004).   
Studies where HIV-positive children were administered a full adult dose of TDF once 
daily showed similar pharmacokinetic changes observed in the initial pharmacokinetic study.  
Children and adolescents (defined as <25 years old) have lower plasma concentrations of TFV 
compared to adult patients and clearance in children was 36% faster, which may contribute to the 
lower plasma concentration.  The increase in clearance may be due to a larger kidney relative to 
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body size as well as increased renal function (Baheti, King, Acosta, & Fletcher, 2013; King et 
al., 2011).  Additionally, Baheti and colleagues (2013) reported that children have almost 50% 
higher intracellular concentrations of TDP following oral administration compared to adults.  
This phenomenon may be due to a lower effective concentration, EC50 seen in children rather 
than adults for TFV (100 ng/mL vs 192 ng/mL respectively). 
Though no significant adverse effects were initially observed in studies using an adult 
dose, studies have also been conducted to determine effective weight-band TDF dosing in 
children due to concerns of bone density loss at different stages of bone dynamics.  Longitudinal 
assessment of available data determined that overall incidence of bone mineral density (BMD) 
loss in children taking TDF at 24-32%; this loss occurs within 6-12 months of initiation of 
treatment and then stabilizes (Aurpibul et al., 2015; Jacobson et al., 2010; O'Brien, Razavi, 
Henderson, Caballero, & Ellis, 2001; Puthanakit et al., 2012; Schtscherbyna et al., 2012).   
  A study conducted in children age 9 to 18 years also saw increased TFV clearance 
relative to adults, although clearance increased with body weight.  Because of the differences in 
clearance, this model recommends prescribing TDF to children based on weight to achieve adult 
AUC:  150 mg at 20-30 kg body weight, 225 mg at 30-40 kg body weight, and the full adult dose 
of 300 mg at over 40 kg bodyweight (Bouazza et al., 2011); no mention of adverse effects was 
made in this study.  Another study conducted based on weight-band dosing in children 3-17 
years determined similar dosing parameters: 150 mg at 15-21 kg body weight, 225 mg at 22-33 
kg body weight, and a full adult dose of 300 mg at >33 kg body weight.  In this 96 week study, 
28% of patients experienced a decrease in BMD by 24 weeks, at which point BMD remained 
constant (Aurpibul et al., 2015).   
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TDF is most commonly administered in children as part of a treatment regimen also 
containing LPV and RTV, unlike adults who are commonly prescribed single dose combination 
tablets (see previous section).  It is relevant to note that LPV increases TDF AUC by 34% and 
serum concentration by 30% in adults (Barditch-Crovo et al., 2001; Kearney et al., 2004).  This 
phenomenon is also seen in children, and is attributed to the observed 25% decrease in TDF 
clearance when co-administered with LPV (Aurpibul et al., 2015; Bouazza et al., 2011).  It is 
recommended that TDF dosing be adjusted in children when co-administered with LPV:  150 mg 
at 20-40 kg body weight, 225 mg at 40-50 kg body weight, and 300 mg at >55 kg body weight 
(Bouazza et al., 2011).   
TDF is approved to treat HIV in children >2 years of age in combination with other 
medications.  It is recommended that dosage be adjusted according to body weight in children 
<12 years of age (Gilead Sciences, 2001).  Additional study needs to be conducted on the 
observed interaction of TDF with LPV, as well as to monitor the incidence of bone density loss 
in children. Additional research is needed to evaluate the effect of age on the renal tubular 
transporters and potential impact on TFV clearance. TFV is a substrate for the efflux transporter 
MRP4.  A study in rats reported that MRP4 expression developed slower than the basolateral 
membrane transporters OAT1 and OAT3 (Nomura, Motohashi, Sekine, Katsura, & Inui, 2012). 
The developmental expression of MRP4 and other transporters is an area of limited information 
and may explain some of the differences related to TFV clearance with age.   
Tenofovir as a Prophylactic Agent: Sex Related Differences in Pharmacokinetics 
TDF is commonly used for antiretroviral pre-exposure chemoprophylaxis (PrEP) in HIV-
uninfected patients who engage in high risk sexual encounters.  Studies evaluating oral TDF/FTC 
PrEP efficacy show modest protection (76%) when taken twice a week and 75-99% infection 
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protection when taken every day.  Studies using oral TDF 300 mg tablets as PrEP show a 67% 
reduction in HIV incidence but high adherence was necessary (Anderson et al., 2012; Baeten et 
al., 2012).  It should be noted that while TFV pharmacokinetics are similar, there are 
documented differences in TDP intracellular concentrations in HIV-infected and uninfected 
patients; TDP concentrations are higher in HIV-infected patients (120 fmol/million cells) than in 
healthy patients (42 fmol/million cells) (Anderson et al., 2012; Baheti et al., 2013).  Currently,  
TDF/FTC is the only FDA approved PrEP regimen; it must be taken daily in conjunction with 
safer sex practices and HIV-status monitoring every three months.  HIV-status monitoring is 
critical as HIV-1 resistance has been documented in cases of undetected infection when using 
TDF/FTC  (Gilead Sciences, 2004).          
  To evaluate PrEP options for women, studies have been conducted to determine the 
efficacy of a topical 1% TDF gel formulation in the prevention of HIV infection.  The original 
CAPRISA clinical trial showed modest protection, with an incidence of reduction ranging from 
39-54% depending on adherence (Abdool Karim et al., 2010).  TDP intracellular concentrations 
were not measured.  A study of PrEP regimens of TDF, TDF/FTC, or 1% TDF vaginal gel in 
African women determined that there was no effect in the prevention of HIV transmission 
(Marrazzo et al., 2015); again TDP concentration was not measured.  Currently 1% gel TDF 
formulation is not approved for PrEP, as efficacy has thus far been shown to be moderate at best.   
  Recently clinical studies were done to determine the differences in TFV-DP distribution 
in healthy women using the TDF 1% gel, TDF 300 mg oral tablet, or both.  TDP vaginal 
concentration was 130-fold higher in patients using the topical gel than oral dosing, but systemic 
TDP concentrations were 56-fold lower.  Combination regimens of oral and topical TDF resulted 
in anal tissue concentrations 3-fold higher than in groups that used the oral formulation alone 
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(Burns, Hendrix, & Chaturvedula, 2015; Hendrix et al., 2013).  Efficacy as a PrEP regimen was 
not directly measured in this study.    
The extremely high vaginal concentrations of TDP may be due in part to hormonal 
regulation. Estradiol increases the amount of TDP present in isolated epithelial cells from the 
female reproductive tract, progesterone has no effect, and estradiol-progesterone combination 
treatment negates the stimulatory effect of estradiol.  In CD4 cells isolated from the female 
reproductive tract, progesterone alone and in combination with estradiol greatly reduced TDP 
concentrations (Shen et al., 2014).  These results suggest that hormonal regulation of TFV 
phosphorylation is dependent on cell type.  It has been hypothesized that women experience a 7-
10 day window of increased susceptibility to HIV-infection due to immune suppression by sex 
hormones following ovulation (Wira & Fahey, 2008).  The changes in TDF-uptake and 
activation in the female reproductive tract may be due to the hormonal responses seen in 
previous studies.        
It is worth noting that while TDP concentrations vary in the female reproductive tract, 
administration of TDF with oral contraceptive pills (OCP) did not change either TFV or OCP 
systemic levels (Kearney & Mathias, 2009).  The observed responsiveness to sex hormones may 
be limited to tissues within the reproductive tract; additional study needs to be done in this area 
to fully determine the relationship between TDF pharmacokinetics and sex hormones.  
TDF has also been examined in late pregnancy and labor to prevent vertical transmission 
of HIV from expectant mothers to their unborn children.  One study gave 300 mg TDF at the 
onset of labor and to neonates within 12 h of birth to infected mothers; a 13 mg/kg neonate dose 
produced intracellular TDP concentrations similar to adult levels (Hirt et al., 2011).  However 
plasma concentration remains low as seen in children taking TDF, and there is a delay in the 
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presence of TDP in neonatal PBMCs.  There was no quantifiable TDP in fetal PBMCs.  The 
delay in TFV phosphorylation could be due to differences in enzyme expression and activity in 
neonates vs. children.  Another study showed similar results:  HIV-infected mothers were given a 
600 mg dose of TDF and neonates were given a 6 mg/kg daily dose, resulting in plasma 
concentrations similar to those seen in adults.  Infant clearance was also equivalent to that seen 
in older children (Mirochnick et al., 2014).    
It is important to note that TDF pharmacokinetics are slightly altered during pregnancy.  
During the third trimester TDF AUC is 20% lower compared to postpartum levels.  This 
transient difference may be directly attributable to increased weight and faster clearance during 
the last trimester of pregnancy (Best et al., 2015).  Additional research needs to be done to 
determine changes in pharmacokinetic parameters during pregnancy, and how these changes 
affect vertical HIV transmission to children.       
Alternative Tenofovir Prodrug Formulations 
 Recently, tenofovir alafenamide (TAF) has undergone phase I-III testing and was 
approved to treat chronic Hepatitis B (HBV) in 2016.  TAF has greater plasma stability, more 
effective cellular loading than TDF, and maintains a similar oral bioavailability at 17%.  TAF 
has a 50% effective concentration (EC50) of 0.005 uM rather than 5 uM seen with TDF, leading 
to significantly less plasma exposure, and, by association, lower systemic side effects (Buti et al., 
2016; Lee et al., 2005; Sax et al., 2015).  TAF underwent phase I-II testing in HIV patients, but 
did not make it to phase III due to the risk of HIV-1 resistance (Gilead Sciences, 2017; 
Markowitz et al., 2014).  
TAF has been approved to replace TDF in fixed-dose combination tablets to treat HIV 
following phase III trials. The combination product of TAF/FTC/COBI/EVG demonstrated 90% 
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virologic success in both treatment naïve and treatment experienced patients with a lower 
incidence of adverse renal and bone effects when compared to TDF/FTC/COBI/EVG (Gilead 
Sciences, 2015b; Mills et al., 2016; Pozniak et al., 2016; Sax et al., 2015; Wohl et al., 2016).  
The combined preparation TAF/FTC demonstrated 93% virologic success when compared to the 
combination of TDF/FTC, with no documented renal tubulopathy in either test group.  It should 
be noted that while TDF/FTC is recommended as a PrEP regimen, TDF/FTC is not  approved for 
PrEP regimen by the FDA as of May 2017 (Gallant et al., 2016; Gilead Sciences, 2015a; Mills et 
al., 2016; Sax et al., 2015).  While TDF is currently FDA approved for HIV-1 treatment in 
patients two years of age and older, TAF fixed dose combinations are only indicated for patients 
greater than 12 years of age.   
The use of liposomes and niosomes has been investigated to improve the bioavailability 
of TDF.  When encapsulated in a liposome made of phospholipids and 7.5% cholesterol, TDF 
had an increased permeability rate across Caco-2 cells (3.71E-07 cm/s) compared to TDF alone 
(4.18E-07 cm/s) (Spinks, Zidan, Khan, Habib, & Faustino, 2017).  When encapsulated in a 
niosome created with sorbitan monoesterate in a 1:1 ratio, >99% of the TDF dose was released in 
vitro within 24 h.  In a subsequent in vivo study in rats, TDF AUC was increased two-fold when 
encapsulated in a niosome compared to TDF alone; Cmax, T1/2, and Tmax were also increased, 
possibly due to increased GI absorption and the release retarding effects of niosomes (Azmin et 
al., 1985; Kamboj, Saini, & Bala, 2014).  No studies have yet been conducted to determine if 
liposomes or niosomes are more efficient in improving TDF bioavailability or if encapsulation is 
effective in humans for the treatment of HIV using TDF. 
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Conclusions 
 TDF is the prodrug for TFV, which is a nucleotide analogue reverse transcriptase 
inhibitor that is very effective in the treatment of HIV and chronic HBV.  TDF has a favorable 
pharmacokinetic profile, allowing for once a day dosing, and its pharmacokinetics are largely 
unchanged when given in fixed-dose combination tablets.  TDF has been shown to be effective 
as a prophylactic agent to prevent HIV-1 transmission, leading to site-specific formulations; this 
area of research remains highly active.  TDF does have limited oral bioavailability, and research 
is ongoing to determine if bioavailability can be increased.  More importantly, TDF improves 
intracellular concentration in PBMCs.  Overall, TDF remains one of the first line agents in the 
treatment of HIV and HBV providing once daily dosing which improves patient compliance.  
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CHAPTER 2 
TENOFOVIR INDUCED NEPHROTOXICITY: THE SCOPE OF THE CURRENT 
WORK 
Tenofovir Induced Nephrotoxicity   
 TDF is the prodrug for TFV which is a nucleotide analogue reverse transcriptase inhibitor 
that is approved in the United States for the treatment of HIV and chronic Hepatitis B.  TDF has 
a favorable pharmacokinetic profile, allowing for once a day dosing and has limited incidence of 
day to day adverse effects; both of these factors are important to increase compliance in chronic 
disease treatment (Barditch-Crovo et al., 2001).  TDF is also effective in both treatment naïve 
and treatment experienced patients, particularly in patients who have developed HIV-1  
resistance (Miller et al., 2001; Squires et al., 2003).  These attributes make TDF a first line agent 
in the treatment of HIV according to the World Health Organization.   
 Despite its many positive attributes, renal toxicity is an adverse effect associated with 
TDF use clinically.  TFV can induce reductions in GFR and free calcitriol, increases in serum 
creatinine and plasma vitamin D binding, renal failure, and in extreme cases Fanconi Syndrome.  
Fanconi syndrome is described as a renal tubular function disorder that results in excess 
excretion of phosphate salts, protein, potassium, glucose, and urate (Del Palacio et al., 2012; Hall 
et al., 2011; Havens et al., 2013).  Clinical studies indicate that the mitochondria of the proximal 
tubules are the target of TFV induced toxicity as shown by enlarged and malformed 
mitochondria in electron microscopy cross sections (Cote et al., 2006; Hall et al., 2011; Herlitz et 
al., 2010; Woodward et al., 2009).  Proximal tubular mitochondrial toxicity has also been 
described in mice and rats treated with TFV as shown by disruptions in mitochondrial cristae and 
a reduction in mtDNA levels (Kohler et al., 2009; Lebrecht et al., 2009).        
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Renal excretion requires both glomerular filtration and tubular secretion.  Following 
glomerular filtration, TFV is transported from blood into proximal tubular epithelial cells by 
organic anion transporters 1 and 3 (OAT1, OAT3, respectively) (Kohler et al., 2011; Uwai, Ida, 
Tsuji, Katsura, & Inui, 2007).  TFV can then undergo tubular secretion into the lumen via the 
multidrug resistant proteins 2 (MRP2) and 4 (MRP4) (Izzedine, Launay-Vacher, & Deray, 2005; 
Kohler et al., 2011).  While there is knowledge of the mechanisms contributing to tubular 
transport, the mechanism of TFV-associated proximal tubule damage is not extensively known at 
this time.  This lack of knowledge is due largely to limited experimental models.  
HK-2 Cell Model 
Mechanistic studies require a model that is consistent with what occurs in humans. The 
selection of suitable models to study TFV cytotoxicity has been problematic as most in vivo 
models require subchronic treatment of animals. TFV toxicity in rodents such as rats has 
required eight weeks of daily treatment in order to develop nephrotoxicity (Lebrecht et al., 
2009). In this study, rats treated for eight weeks exhibited diminished renal function and 
proximal tubular damage along with enlarged mitochondria. Another study showed that 
treatment for five weeks with TFV induced oxidative stress in Wistar rats dosed with very high 
levels of TFV (Abraham, Ramamoorthy, & Isaac, 2013).  
An in vitro model was first reported by Wang and Flint (2013) that developed TFV 
cytotoxicity using primary human kidney cells (Wang & Flint, 2013). Primary human kidney 
cells required culturing for 19 days with 200 μM TFV to induce cytotoxicity, which was a long 
duration at concentrations higher than pharmacological levels. The need for higher 
concentrations of TFV to induce toxicity in primary proximal tubule cell lines may be due to 
differences in OAT1 and OAT3 expression. Endogenous expression of OAT1 and OAT3 in 
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primary human proximal tubule cells has been shown to vary greatly from sample to sample 
(Lash, Putt, & Cai, 2006) and TFV-induced cytotoxicity is dependent on OAT1 and OAT3 
expression (Kohler et al., 2011; Nieskens et al., 2016). 
 Renal toxicity was diminished in OAT1 knockout mice, indicating that OAT1 has a 
primary contribution to TFV renal uptake into proximal tubular epithelial cells (Kohler et al., 
2011). In vitro studies reported that HEK293 cells transfected with OAT1 were much more 
sensitive to TFV cytotoxicity than cells transfected with OAT3 (Izzedine et al., 2005); further, 
intracellular TFV concentrations were higher in HEK-OAT1 transfected cells compared to wild 
type and these findings support the concept that OAT1 is important for TFV uptake. 
Human Kidney 2 (HK-2) cells were selected as a model to investigate the in vitro 
cytotoxicity of TFV.  HK-2 cells are an immortalized, noncancerous, human epithelial proximal 
tubular cell line that maintains activity and biochemical properties similar to in vivo proximal 
tubule cells (Gunness, Aleksa, Kosuge, Ito, & Koren, 2010; Paolicchi et al., 2003; Ryan et al., 
1994).  HK-2 cells express OAT1 and OAT 3, which are necessary to transport TFV into 
proximal tubule cells as well as multidrug resistance protein 4 (MRP4), which is necessary for 
efflux from the proximal tubule cell (Miyamoto et al., 2012).  HK-2 cells are commonly used to 
study drug toxicity and in mechanistic studies as they eliminate potential species differences that 
occur in porcine, dog, and mouse cell lines (Andreucci et al., 2015; Gunness et al., 2010; Jia, Ha, 
Yang, Chang, & Yang, 2011; Kondo, Inamura, Matsumura, & Matsuoka, 2012).  This thesis 
establishes that HK-2 cells are a viable model to study TFV induced cytotoxicity as well as 
utilize them to gain insight into the mechanism of this toxicity.      
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Statement of Hypothesis 
 Current published studies have determined that TFV induces damage to proximal tubule 
epithelial cells.  The purpose of my dissertation was to investigate a mechanistic understanding 
of TFV induced cytotoxicity and investigate potential methods to mitigate or prevent it.  To that 
end, I tested the following hypotheses in this work.  First, TFV is toxic to HK-2 cells at clinically 
relevant concentrations.  Second, the mechanism of this toxicity is due to oxidative stress and 
mitochondrial dysfunction.  Lastly, pretreatment with antioxidants mitigates TFV induced 
cytotoxicity.  
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CHAPTER 3 
ESTABLISHMENT OF HK-2 CELLS AS A RELEVANT MODEL TO STUDY 
TENOFOVIR-INDUCED CYTOTOXICITY 
A manuscript published in the International Journal of Molecular Sciences.  
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"Establishment of HK-2 Cells as a Relevant Model to Study Tenofovir-Induced 
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Abstract 
 Tenofovir (TFV) is an antiviral drug approved for treating Human Immunodeficiency 
Virus (HIV) and Hepatitis B. TFV is administered orally as the prodrug tenofovir disoproxil 
fumarate (TDF) which then is deesterified to the active drug TFV. TFV induces nephrotoxicity 
characterized by renal failure and Fanconi Syndrome. The mechanism of this toxicity remains 
unknown due to limited experimental models. This study investigated the cellular mechanism of 
cytotoxicity using a human renal proximal tubular epithelial cell line (HK-2). HK-2 cells were 
grown for 48 h followed by 24 to 72 h exposure to 0–28.8 µM TFV or vehicle, phosphate 
buffered saline (PBS). MTT (MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromide) and Trypan blue indicated that TFV diminished cell viability at 24–72 h. TFV 
decreased ATP levels at 72 h when compared to vehicle, reflecting mitochondrial dysfunction. 
TFV increased the oxidative stress biomarkers of protein carbonylation and 4-hydroxynonenol 
(4-HNE) adduct formation. Tumor necrosis factor alpha (TNFα) was released into the media 
following exposure to 14.5 and 28.8 µM TFV. Caspase 3 and 9 cleavage was induced by TFV 
compared to vehicle at 72 h. These studies show that HK-2 cells are a sensitive model for TFV 
cytotoxicity and suggest that mitochondrial stress and apoptosis occur in HK-2 cells treated with 
TFV. 
Introduction 
Tenofovir disoproxil fumarate (TDF) is a nucleotide reverse transcriptase inhibitor that is 
approved in the United States to treat Human Immunodeficiency Virus (HIV) and chronic 
Hepatitis B. Tenofovir (TFV) is administered as the prodrug TDF; TDF was designed to improve 
the bioavailability of TFV by the addition of 2-methyl carbonate esters which are deesterified to 
the active drug TFV (Shaw et al., 1997). TFV is efficacious to both treatment-naïve and 
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treatment-experienced patients and has been beneficial in patients that have acquired resistance 
to other HIV medications (Dore et al., 2004; Miller et al., 2001). TFV is considered a first line 
agent essential for treatment of HIV by the World Health Organization. TFV is the only 
antiretroviral that is a nucleotide analogue reverse transcriptase inhibitor. Compliance is higher 
with TFV than with other antiretroviral agents due to fewer side effects and once daily dosing 
(Barditch-Crovo et al., 2001). 
Despite many positive therapeutic attributes, an adverse effect of TFV is nephrotoxicity. 
TFV-induced nephrotoxicity is characterized by a decreased glomerular filtration rate (GFR), 
increased serum creatinine, renal failure, and Fanconi-like Syndrome (Del Palacio et al., 2012; 
Hall et al., 2011). Fanconi Syndrome is a proximal tubular transport abnormality associated with 
impaired tubular reabsorption resulting in excess glucose, protein, urate, and phosphate 
excretion. 
Renal excretion requires both glomerular filtration and tubular secretion. TFV is 
transported from blood into proximal tubular epithelial cells by organic anion transporters 1 and 
3 (OAT1, OAT3, respectively) (Kohler et al., 2011; Uwai et al., 2007). Renal toxicity was 
diminished in OAT1 knockout mice, indicating that OAT1 has a primary contribution to TFV 
renal uptake into proximal tubular epithelial cells (Kohler et al., 2011). In vitro studies reported 
that HEK293 cells transfected with OAT1 were much more sensitive to TFV cytotoxicity than 
cells transfected with OAT3 (Zhang, Piotrowski, Zhang, Leach, 2015); further, intracellular TFV 
concentrations were higher in HEK-OAT1 transfected cells compared to wild type and these 
findings support the concept that OAT1 is important for TFV uptake. The drug can then undergo 
tubular secretion into the lumen via the multidrug resistant proteins 2 (MRP2) and 4 (MRP4) 
(Izzedine et al., 2005; Kohler et al., 2011). While there is knowledge of the mechanisms 
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contributing to tubular transport, the mechanism of TFV-associated proximal tubule damage is 
not extensively known at this time. This knowledge gap is due largely to limited experimental 
models; in vivo studies have used TFV treatment for three to eight weeks (Lebrecht et al., 2009; 
Ramamoorthy, Abraham, & Isaac, 2014), or primary renal cells exposed for up to 22 days (Vidal 
et al., 2006). The long duration of these experiments is not ideal and can hamper mechanistic 
studies. Additionally, daily treatment of rats for an extended period can cause significant stress, 
adding other complications to a mechanistic study. Cell lines can circumvent the contribution of 
stress as well as eliminate extrarenal factors and hemodynamics. 
The purpose of this study was to explore the in vitro cytotoxicity of TFV in HK-2 cells. 
We selected Human Kidney 2 (HK-2) cells as a model as these cells are an adult, noncancerous, 
immortalized human epithelial cell line. HK-2 cells maintain biochemical properties and activity 
similar to in vivo proximal tubule cells (Gunness et al., 2010; Paolicchi et al., 2003; Ryan et al., 
1994). Additionally, HK-2 cells express OAT1 and OAT3 proteins (Miyamoto et al., 2012), 
which facilitate TFV transport into proximal tubule cells. 
In this manuscript, we demonstrate that the HK-2 cell is a viable model to study TFV-
induced cytotoxicity at clinically relevant concentrations. Further, these studies revealed that 
oxidative stress, induction of apoptosis, and mitochondrial decline in ATP are associated with 
TFV renal cytotoxicity. 
Results  
 TFV Effects on Cell Viability  
Based on the MTT (MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromide)) assay, TFV reduced cell viability within 24 h (p < 0.05) at all tested concentrations 
(Figure 4). MTT values continued to show diminished cell viability at 48 and 72 h (p < 0.001) 
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for all TFV concentrations when compared to vehicle control (Figure 4). TFV final 
concentrations of 4.75 and 14.5 µM showed additional decline in cell viability at 72 h compared 
to other treatment groups (p < 0.05) (Figure 4). Trypan blue exclusion and cell counts were 
conducted in order to confirm that the TFV mediated decline in formazan formation could not be 
attributed to a direct effect of TFV on mitochondrial reductase enzymes converting MTT to 
formazan. Trypan blue cell counts (Figure 5) confirmed that TFV diminished cell viability 
beginning at 24 h and continuing for 72 h when compared to vehicle control. There was no 
difference in cell viability between groups. IC50 values calculated using MTT data were 9.21 
and 2.77 µM TFV at 48 and 72 h, respectively. MTT viability studies conducted with the less 
nephrotoxic antiviral agent, abacavir, indicated that abacavir did not reduce cell viability at 24 h 
(Figure 4D) suggesting that our model is an appropriate model to examine nephrotoxic agents. 
Further experiments were initiated with TFV to explore the cellular mechanism of TFV 
cytotoxicity. 
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Figure 4. Tenofovir cytotoxic effects on cell viability in HK-2 cells using MTT. Tenofovir 
diminished cell viability at 24 (A), 48 (B) and 72 h (C). Statistical difference from 0 μM 
tenofovir depicted in (A and B) by asterisks (* p < 0.05, *** p < 0.001). Different superscript 
letters (C) indicate groups that are different from each other (p < 0.05); (D) depicts cell viability 
following exposure for 24 h to another antiviral agent, abacavir. Abacavir did not alter viability 
at the concentrations tested. Each bar represents Mean ± SEM for three independent experiments 
run with two biological replicates. 
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Figure 5. Tenofovir cytotoxic effects on cell viability in HK-2 cells using Trypan Blue 
Exclusion. Tenofovir diminished cell viability at 24 (A), 48 (B) and 72 h (C). Statistical 
difference from 0 μM tenofovir is denoted by asterisks (*** p < 0.001). Each bar represents 
Mean ± SEM for three independent experiments run with two biological replicates. 
 
TFV Effects on Mitochondrial Function  
Our hypothesis was that TFV impairs mitochondrial function resulting in decreased ATP 
levels. ATP levels were unchanged compared to vehicle by TFV after 24 or 48 h incubation 
(Figure 6). ATP levels were diminished by all concentrations of TFV at 72 h when compared to 
vehicle (p < 0.001) (Figure 6). These results suggest that multiple mechanisms of cytotoxicity 
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may be induced by TFV since the reduction in ATP levels was not apparent prior to a reduction 
in cell viability. 
Figure 6. Tenofovir effects on ATP levels in HK-2 cells. ATP levels were measured following 
24 (A), 48 (B) and 72 h (C) exposure to tenofovir. ATP was measured using an ATP Assay kit 
(Biovision) and simultaneously run ATP standards. Statistical difference from 0 μM tenofovir 
denoted by asterisks (*** p < 0.001). ATP levels at 24 and 48 h represent Mean ± SEM for two 
independent experiments run with three biological replicates. ATP levels at 72 h represent Mean 
± SEM for four independent experiments run with three biological replicates. 
  
 TFV Effects on Oxidative Stress  
TFV increased oxidative stress as shown by Oxyblot analysis at 72 h relative to control in 
groups treated with 14.5 and 28.8 μM TFV (p < 0.001, Figure 7). Protein carbonylation was not 
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increased relative to control at 48 h or at lower TFV concentrations at 72 h. 4-HNE adduct 
formation was increased following 72 h exposure for treatment groups of 3.0 to 28.8 μM TFV 
(Figure 8). TNFα secretion into the media was increased at 72 h exposure to TFV compared to 
vehicle (p < 0.001). TNFα expression in cell lysate was decreased at 48–72 h (p < 0.05) as 
shown by Western blot (Figure 9). These results suggest that TNFα is released into the media as 
TFV cytotoxicity occurs and that TFV does not increase TNFα protein expression. TNFα 
expression in the TFV treated cells was similar to vehicle control at 24 h when cell viability was 
diminished. These results suggest that it is unlikely that TNFα is the primary event in the 
mechanism of TFV cytotoxicity but rather occurs as a result of initial toxicity. The subcellular 
generation of oxidative stress may be due to mitochondrial damage, as ATP levels were also 
diminished by TFV. It is still not clear if TFV directly damages the mitochondria, leading to 
oxidative stress, or if TFV induces reactive oxygen species that subsequently damage 
mitochondria; additional studies are needed to further explore the mechanism of cytotoxicity.  
34 
Figure 7. Tenofovir treatment for 72 h increased protein carbonylation in HK-2 cells. 
Protein carbonylation was measured in HK-2 cell lysate following 48 (A) and 72 h (B) exposure 
to TFV. Representative gel and cumulative densitometry included in each panel. Representative 
blot with MemCode Reversible staining for equal 25 μg protein loading and cumulative protein 
densitometry depicted for 48 (C) and 72 h (D) exposure. Asterisks (** p < 0.01, *** p < 0.001) 
indicate statistical difference from the vehicle control group. Each bar represents Mean ± SEM 
for three independent experiments run with three biological replicates. 
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Figure 8. Tenofovir effects on 4-HNE adduct formation in HK-2 cells. 4-HNE adduct 
formation was measured in HK-2 cell lysate following 48 h (A) and 72 h (B) exposure to TFV. 
Representative gels and cumulative densitometry included in each panel. Representative blot 
with MemCode Reversible staining for equal 40 μg protein loading and cumulative protein 
densitometry depicted for 48 h (C) and 72 h (D) exposure. Asterisks (* p < 0.05, *** p < 0.001) 
indicate statistical difference from the vehicle control group. Each bar represents Mean ± SEM 
for three independent experiments run with three biological replicates.  
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Figure 9. TNFα expression in HK-2 cell lysate and media following tenofovir exposure. (A) 
TNFα release into media expressed as a percent of control following 24, 48, and 72 h TFV 
exposure. TNFα in media was increased following a 72 h exposure for all concentrations relative 
to control (*** p < 0.001). (Panel B) provides representative blot and cumulative densitometry 
for TNFα expression in cell lysate following 24, 48, 72 h TFV exposure. Statistical difference 
from 0 μM tenofovir depicted by asterisk (* p < 0.05); (C) depicts cumulative densitometry and 
representative blots for 50 μg protein loading of cell lysates visualized with MemCode 
Reversible Protein staining. Each bar represents Mean ± SEM for two independent experiments 
run with three biological replicates. 
 
 TFV Effects on Apoptosis Initiation  
TFV increased cleaved caspase 3 (p < 0.0.05) and cleaved caspase 9 relative to control 
for all treatments at 72 h exposure (Figure 10). Caspase 8 expression was measured after 48 and 
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72 h exposure to TVF. TFV did not increase caspase 8 cleavage relative to control at either time 
point. Cleaved caspase 8 was minimal in all groups and was decreased by higher TFV treatment 
relative to vehicle control. These results suggest that the increase in TNFα in the media at 72 h 
was not sufficient to stimulate caspase 8 cleavage. These data show that TFV induces apoptosis 
in HK-2 cells, and that apoptosis is induced via mitochondrial damage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Cont’d.  
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Figure 10. Tenofovir effects on the expression of cleaved caspase 3, 8 and 9 in HK-2 cells. 
Representative blot and cumulative densitometry for cleaved to total caspase 9 (A), caspase 3 (B) 
and caspase 8 (D) protein expression following 72 h. Asterisks (* p < 0.05, ** p < 0.01, *** p < 
0.001) indicate statistical difference from the vehicle control group; (C) Depicts 48 h caspase 8 
cleavage. (E) representative blots of MemCode reversible staining for 40 μg protein loading and 
cumulative densitometry; blots and densitometry depicted (from left to right) are for (A) (72 h 
Caspase 3), (B) (72 h Caspase 9), (C) (48 h Caspase 8), and (D) (72 h Caspase 8). Each bar 
represents Mean ± SEM for three independent experiments run with three biological replicates. 
 
 Ascorbic Acid Protection of TFV Cytotoxicity  
Oxidative stress was increased by TFV resulting in increased protein carbonylation 
(Figure 4) and increased 4-HNE protein adduction (Figure 5) suggesting that a rise in reactive 
oxygen species occurs with TFV cytotoxicity. Pretreatment with ascorbic acid reduced TFV 
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toxicity in HK-2 cells (Figure 11) as cell viability was higher in cells exposed to TFV in the 
presence of ascorbic acid compared to TFV alone. These findings suggest that an antioxidant can 
reduce TFV cytotoxicity in HK-2 cells. 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Effects of ascorbic acid on tenofovir cytotoxicity. Ascorbic acid did not alter cell 
viability relative to vehicle control. Ascorbic acid protected HK-2 cells from tenofovir 
cytotoxicity as assessed by MTT viability. An asterisk (* p < 0.05) indicates statistical difference 
from all other groups. Values represent Mean ± SEM for three independent experiments run with 
three biological replicates. 
 
Discussion  
TFV is a very effective antiviral nucleotide reverse transcriptase inhibitor prescribed 
worldwide in the treatment of HIV and Hepatitis B. Patients treated with TFV have an increased 
incidence of renal impairment (Fux et al., 2007; Verhelst et al., 2002). Renal TFV toxicity in 
humans is characterized by Fanconi Syndrome, and depending on the dose, development of 
irreversible impaired renal function. There is a positive correlation between increased TFV 
40 
plasma concentration, renal toxicity and the duration that patients were treated with TFV Ezinga 
et al., 2014; Quesada et al., 2015) because treatment with TFV is chronic, examination of the 
mechanism of renal toxicity is clinically relevant. Understanding the mechanism is essential for 
the development of methods to mitigate TFV renal impairment. 
Mechanistic studies require a model that is consistent with what occurs in humans. The 
selection of suitable models to study TFV cytotoxicity has been problematic as most in vivo 
models require subchronic treatment of animals. TFV toxicity in rodents such as rats has 
required eight weeks of daily treatment in order to develop nephrotoxicity (Lebrecht et al., 
2009). In this study, rats treated for eight weeks exhibited diminished renal function and 
proximal tubular damage along with enlarged mitochondria. Another study showed that 
treatment for five weeks with TFV induced oxidative stress in Wistar rats dosed with very high 
levels of TFV (Abraham et al., 2013).  
An in vitro model was first reported by Wang and Flint (2013) that developed TFV 
cytotoxicity using primary human kidney cells (Wang & Flint, 2013). Primary human kidney 
cells required culturing for 19 days with 200 μM TFV to induce cytotoxicity, which was much 
longer and at concentrations higher than pharmacological levels. The need for higher 
concentrations of TFV to induce toxicity in primary proximal tubule cell lines may be due to 
differences in OAT1 and OAT3 expression. Endogenous expression of OAT1 and OAT3 in 
primary human proximal tubule cells has been shown to vary greatly from sample to sample 
(Lash, Putt, & Cai, 2006) and TFV-induced cytotoxicity is dependent on OAT1 and OAT3 
expression (Kohler et al., 2011; Nieskens et al., 2016). Our HK-2 cell model is more sensitive 
than human primary proximal tubule cells as we have shown induction of cytotoxicity in 24 h 
compared to 22 days and at a concentration almost ten times lower than reported for human 
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primary proximal tubular epithelial cells (Vidal et al., 2006). In addition to inducing cytotoxicity 
at 24 h, our HK-2 cell model has an IC50 of 9.2 μM TFV at 48 h, and an IC50 of 2.77 μM TFV at 
72 h. Other cell types such as HEK293 cells have been used to study tenofovir cytotoxicity, but 
appear less sensitive than our HK-2 model. One study showed that TFV-induced cytotoxicity 
within 48 h in HEK293 cells transfected with OAT1; however, the IC50 was reported to be 316 
μM (Zhang et al., 2015).  
Our study is the first to show that HK-2 cells can be used to evaluate TFV cytotoxicity. 
TFV renal cytotoxicity was evident within 24 h at clinically relevant concentrations. Primary 
human kidney cells required a concentration of 200 μM, which is higher than reported maximal 
clinical steady state plasma concentration (Wang & Flint, 2013). In comparison, in our study, 
viability was diminished in HK-2 cells with TFV concentrations ranging from 1.5 to 28.8 μM. 
The concentrations used in our current study are clinically relevant as plasma TFV 
concentrations have been reported to be 2.2 μM in HIV-1 infected patients (Barditch-Crovo et 
al., 2001; Zhang et al., 2015). Additionally, TFV plasma concentrations are higher in HIV-1 
patients and non-infected individuals with existing renal impairment; patients with renal 
impairment also experience a longer duration of TFV exposure, as shown by a 15-fold increase 
in AUC0–24 h ( Custodio et al. 2016; Ezinga et al. 2014; Sentenac, Fernandez, Thuillier, Lechat, 
and Aymard, 2003). Therefore, HK-2 cells provide a model that can be used to examine the 
mechanism of toxicity without the compounding physiological parameters influencing the 
response of the kidney to a toxicant. Our studies further showed that HK-2 cells can differentiate 
the toxicity of different antiviral agents as abacavir, an agent that is considered less toxic to the 
kidney which was not toxic in our system (Figure 4D).  
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It is probable that TFV renal cytotoxicity involves multiple mechanisms and that these 
mechanisms are not yet fully understood. TFV treatment of HK-2 cells decreased ATP levels 
when compared to control at 72 h exposure (Figure 6). Diminished ATP levels can be mediated 
by numerous pathways, including alterations in mitochondrial DNA stability, impaired 
mitochondrial function, or increased oxidative stress.  
Mitochondrial function relies on many factors, including the stability and integrity of 
mitochondrial DNA (mtDNA). Decreased mtDNA could result in a decline in cellular ATP 
levels. There are conflicting reports regarding the effects of TFV on mtDNA. The differences 
may be due to species variation and differences in experimental models. For example, TFV 
diminished mtDNA in HIV-1 transgenic mice (Kohler et al., 2009) while a 19 day exposure of 
human primary renal proximal tubule cells to 2 and 200 μM TFV showed no change in mtDNA 
compared to control (Paolicchi et al., 2003; Wang & Flint, 2013). However, effects of TFV on 
mtDNA may vary between renal and nonrenal cells (Wang & Flint, 2013). Additionally, mtDNA 
was diminished in human primary proximal tubule cells by another nucleoside reverse 
transcriptase inhibitor, adefovir, within nine days of incubation with TDF (Wang & Flint, 2013), 
indicating that TFV may be a weaker inhibitor of DNA polymerase gamma.  
TFV increased expression at 72 h of cleaved caspase 3 and 9 in HK-2 cells (Figure 10). 
Apoptosis can be induced via many pathways, including extracellular signals and mitochondrial 
dysfunction. Each pathway activates different initiator caspase proteins; for example, cleavage of 
caspase 9 occurs when mitochondrial damage initiates the intrinsic apoptotic pathway. Initiator 
caspases then interact with other cellular proteins, forming an apoptosome that cleaves 
executioner caspases such as caspase 3 and activates the induction of cell death. The increased 
expression of cleaved caspase 3 and 9 in HK-2 cells treated with TFV indicated that apoptosis 
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was occurring, and that mitochondrial dysfunction may be a major contributing factor to loss of 
cell viability (Figure 10).  
The renal proximal tubular epithelial cell has a high requirement for ATP generation to 
maintain normal cellular processes such as active transport. The decline in cellular ATP levels 
caused by TFV would impair normal proximal tubular epithelial cell function. TFV increased 
oxidative stress, as protein carbonylation was elevated at 72 h exposure to 14.5 and 28.8 μM 
TFV (Figure 7). The HK-2 cells were more sensitive to TFV and displayed increased oxidative 
stress at clinically relevant concentrations as compared to previously examined models. A five 
week treatment of rats with 12 times higher dose than what is clinically used reported a 25% 
increase in renal protein carbonylation (Abraham et al., 2013); the HK-2 cells demonstrated a 
much greater increase in protein carbonylation within a shorter time period than reported in vivo 
treatment of rats (Figure 7), suggesting that HK-2 cells may be a more sensitive model to 
examine TFV cytotoxicity.  
TNFα is a proinflammaotry cytokine which is expressed in proximal tubular epithelial 
cells. TNFα can be secreted from cells to induce an inflammatory response as a protective 
mechanism during initial exposure to toxicants (Gu, Xing, Xu, & Lu, 2016). TNFα expression 
can induce reactive oxygen species generation via mitochondria and through activation of 
NADPH oxidase (Morgan, 2010). Mitochondrial damage and generation of reactive oxygen 
species can stimulate the release of various cytokines including TNFα (Mittal, Siddiqui, Tran, 
Reddy, & Malik, 2014). These changes in TNFα expression and secretion can modulate various 
parts of the cellular antioxidant system and directly increase the production of mitochondrial 
reactive oxygen species through damage to the electron transport chain. In experiments involving 
exposing HK-2 cells to toxicants and/or ischemic injury, TNFα levels rose along with many 
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other markers of toxicity, including increases in oxidative stress via dysfunction of cellular 
antioxidant systems, activation of an inflammatory response and associated proteins, and 
induction of programmed cell death (Gong, Ivanov, Davidson, & Hei, 2015; Zager, Johnson, & 
Geballe, 2007; Zhang et al., 2013). We examined TNFα as a potential indicator of oxidative 
stress. Our study showed that TNFα was released into the media at 72 h, while tissue showed a 
decline in expression at 48 and 72 h (Figure 9). Because TNFα expression was unaltered at 24 h 
(Figure 9) it is unlikely that activation of inflammatory response is the cause of the oxidative 
stress observed. The decline in TNFα in the cells is consistent with loss from cells into the 
media; TNFα released into the media may contribute to greater oxidative stress. Further studies 
need to explore the cellular mechanism for increased oxidative stress, TNFα secretion in HK-2 
cells, specifically, evaluation of mitochondrial alterations that may mediate either a decline in 
mitochondrial function or increased reactive oxygen species. 
Methods  
 Chemicals and Reagents  
TFV was purchased from Cayman Chemicals (Item No. 13874, Ann Arbor, MI, USA) 
and was used for all studies. The vehicle for cell treatments was phosphate buffered saline 
(Invitrogen, Carlsbad, CA, USA, Item No. 14175095). MTT and other chemicals were purchased 
from Sigma Aldrich (St. Louis, MO, USA) or Fisher Scientific (Pittsburg, PA, USA). Antibodies 
and kits were purchased as indicated in the sections below.  
Cell Lines and Tenofovir (TFV) Treatment  
Human immortalized epithelial HK-2 cells were purchased from the American Type 
Culture Collection (ATCC) and were cultured according to ATCC guidelines. Briefly, cells were 
grown in a keratinocyte-free media with 50 μg/mL bovine pituitary extract and 5 ng/mL 
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recombinant epithelial growth factor from Invitrogen (Carlsbad, CA, USA, Item No. 17005-042). 
Cells were grown in a warm humidified incubator with constant settings of 37 °C and 5% CO2. 
HK-2 cells were plated into six-well tissue culture plates (750,000 cells/mL) (Corning, Sigma 
Aldrich Item No. CLS3516) and allowed to grow for 48 h. Media was replaced and cells were 
treated with a final concentration of 0, 1.5, 3.0, 4.75, 14.5, or 28.8 μM TFV for 24, 48, or 72 h. 
The vehicle was an equal volume of phosphate buffered saline (PBS). Abacavir was prepared in 
sterile water and cells were treated for 24 h with 0, 1.5, 3 or 6 μM of abacavir to evaluate renal 
sensitivity to an agent recognized to be less nephrotoxic. Following the treatment period, cells 
were collected with Trypsin-EDTA (0.25%) (Invitrogen, Item No. 25200072) for sample 
analysis.  
Cell Viability  
Cells were plated into 48-well tissue culture plates (39,000 cells/mL) (Cyto One, USA 
Scientific, Ocala, FL, USA, Item No. CC7682-7548) and allowed to grow for 48 h followed by 
treatment with vehicle or TFV. Following the treatment period, cell viability was assessed using 
the MTT assay (Humphrey, Cole, Pendergrass, & Kiningham, 2005). The MTT assay relies on 
the conversion of tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) (Sigma Aldrich, Item No. M5655-5X1G) to formazan by NAD(P)H-dependent 
oxidoreductases.  
To ensure that results of the MTT Assay were not due to mitochondrial damage rather 
than cell death, a trypan blue exclusion test was run based on a previously published protocol. In 
brief, an aliquot of collected cells are diluted 1:10 with 40% w/v Trypan Blue solution (Sigma 
Aldrich, Item No. T6146). The suspension was mixed via pipetting and allowed to sit for 
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approximately 2 min. A 10 μL aliquot of suspension was transferred to a hemocytometer and 
total cells, live cells, and dead cells were manually counted. 
ATP Measurement  
ATP levels were assessed using the ADP/ATP Ratio Bioluminescence Assay Kit 
(Biovision Inc., Milpitas, CA, USA, Item No. K255-200). Briefly, 100 μL of reaction mix was 
plated into a 96-well plate (Corning, Sigma Aldrich, Item No. 356519) and allowed to establish a 
baseline during a 2 h room temperature incubation. A 10 μL aliquot of the sample was added to 
each well and bioluminescence was measured using a luminometer. Immediately following the 
measurement, 10 μL of diluted ADP-converting enzyme was added and bioluminescence was 
measured again. Lysate concentration of ATP and ADP was determined using a standard curve.  
Western Blot  
Western blot analysis was conducted to assess the expression of active caspase 3, 8 and 9 
and the formation of 4-hydroxy-2-nonenal (4-HNE) protein adducts. Protein concentration in 
each sample was determined using the Bradford protein assay (Bradford, 1976).  A 40 µg aliquot 
of each sample was denatured by boiling for five min. Proteins were then separated on a 12.5% 
polyacrylamide gel and transferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA, 
Item No. 1620115); successful transfer and protein loading were verified using MemCode 
Reversible Protein Stain Kit (Pierce Biotechnology, Rockford, IL, USA, Fisher Scientific, Item 
No. PI-24580). Membranes were blocked using either a 5% w/v milk/TBST solution (10 mM 
Tris-HCl, 150 mM NaCl, 0.1% Tween-20; pH 8.0) or a 1% Bovine Serum Albumin 
(BSA)/TBST solution for 1 h. Membranes were next incubated with continual shaking overnight 
at 4 ◦C with a rabbit polyclonal antibody for caspase 3 (1:1000 dilution, Cell Signaling 
Technology, Danvers, MA, USA, Item No. 9662), caspase 8 (1:400 dilution, Biovision Inc., Item 
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No. 3020-100), caspase 9 (1:1000 dilution, Cell Signaling Technology, Item No. 9502) or 4-
HNE (1:1000 dilution, Cell Bio Labs Inc., San Diego, CA, USA, Item No. STA-035) diluted in 
5% milk/TBST or 1% BSA/TBST. The membranes were washed four times with TBST and goat 
anti-rabbit HRP-linked secondary antibodies were diluted to 1:5000 in 5% milk/TBST and added 
for 1 h. Membranes were washed again with TBST and then developed using Amersham ECL 
Western Blotting Detection Agent (GE Healthcare Life Sciences, Marlborough, MA, USA, Item 
No. RPN2232). A BioRad chemic-doc system was used to capture the gel image and used for 
densitometry analysis. 
Oxidative Stress  
In addition to 4-HNE adduction of protein, another indicator of  oxidative  stress  is 
protein carbonylation, which can produce an aldehyde or ketone side chain on  amino  acids. 
Protein carbonylation was analyzed using the Oxyblot Protein Oxidation Detection Kit (EMD 
Millipore, Billerica, MA, USA, Item No. S7150). Following treatment for 24–72 h with vehicle 
or TFV, cells were pelleted, rinsed with 500 µL PBS, and centrifuged. The pellet was then 
disrupted with lysis buffer. Protein content was measured, and a 25 µg aliquot was derivatized as 
previously described (Terneus, Kiningham, Carpenter, Sullivan, & Valentovic, 2007). Protein 
carbonyl moieties on amino acids generated by oxidative stress are derivatized in the presence of 
2,4-dinitrophenylhydrazine to stable 2,4-dinitrophenylhydrazone groups. The primary antibody 
recognizes 2,4-dinitrophenylhydrazone groups on proteins and was used at a dilution of 1:150. 
Protein loading was verified using the MemCode Protein Stain and results were analyzed with 
BioRad Chemidoc densitometry software (version 4.0.1, Catalog No. 170-9690, BioRad, 
Hercules, CA, USA). A series of studies examined whether ascorbic acid, an antioxidant, could 
provide protection from TFV. HK-2 cells were allowed to grow for 48 h followed by a one h 
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pretreatment with 0 or 10 µM ascorbic acid in sterile water followed by a 24 h incubation with 0 
or 14.5 µM TFV. Viability of cells was assessed using the MTT assay. All media and MTT was 
removed from the cells prior to the addition of DMSO to prevent any interaction of ascorbic acid 
with formazan. 
TNFα in Cell Media and Cell Lysate  
Proximal tubular epithelial cells express TNFα. TNFα expression was measured in cell 
culture media using an ELISA assay kit and in cell lysate by Western blot. Release of TNFα into 
the cell culture media was measured using an ELISA kit (Abcam, Cambridge, MA, USA, Item 
No. ab181421) per the manufacturer’s instructions. Briefly, 50 µL of collected media and a 
capture/detector antibody cocktail were added to precoated wells and incubated for 1 h shaking 
at 400 rpm. Following the immunocapture incubation period, the wells were washed and TMB 
(TMB, 3,3t,5,5t-Tetramethylbenzidine) substrate was added, producing a color change based on 
the amount of bound TNFα, which was then read at 450 nm. TNFα concentration was 
determined using a standard curve. TNFα expression in TFV treated cell lysate was determined 
using Western blot as described above. Each lane was loaded with 50 µg of protein; membranes 
were probed using a rabbit-polyclonal HRP-linked antibody for TNFα diluted to 1:1000 in 5% 
BSA/TBST (Abcam, Item No. ab66579). TNFα was normalized to protein and compared relative 
to control. 
Statistical Analysis  
Values represent Mean ± SEM with 2–4 independent experiments conducted with 2–4 
biological replicates. Differences between groups were determined with a one-way ANOVA 
followed by a Holm–Sidak post-hoc test with p < 0.05 (SigmaStat, SSPS, Systat Software, 
Chicago, IL, USA, Item Sigma Plot SPW11). 
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Conclusions  
 HK-2 cells are a sensitive mode for examining TFV renal cytotoxicity. The 
concentrations of TFV used in these studies are clinically relevant. Intracellular concentrations of 
TFV can be higher than plasma levels as proximal tubule cells utilize active transport. TFV 
reduced cell viability within 24 h. This is the first report to characterize TFV toxicity using HK-2 
cells. Our results show that TFV causes mitochondrial damage resulting in diminished cellular 
ATP levels and cleavage of caspase 3 and 9. Further studies are needed to explore the specific 
cellular mechanism of mitochondrial toxicity and oxidative stress. The study also showed that 
ascorbic acid, an antioxidant, could reduce TFV cytotoxicity. 
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CHAPTER 4 
ANTIVIRAL AGENT TENOFOVIR CAUSES MITOCHONDRIAL DAMAGE AND 
OXIDATIVE STRESS IN HK-2 CELLS  
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Abstract  
 Tenofovir (TFV) is an antiviral drug approved in the United States for treating Human 
Immunodeficiency Virus (HIV) and Hepatitis B. TFV is administered orally as the prodrug 
tenofovir disoproxil fumarate (TDF) which then is deesterified to the active drug TFV. TFV 
induces nephrotoxicity characterized by decreased glomerular filtration rate (GFR), renal failure, 
and Fanconi Syndrome. The mechanism of this toxicity remains largely unknown due to limited 
experimental models.  In a previously published study, we determined that TFV reduces cell 
viability, causes oxidative stress, and induces apoptosis in the human renal proximal tubular cell 
line (HK-2).  This study further investigated the cellular mechanism of cytotoxicity using HK-2 
cells. HK-2 cells were grown for 48 h followed by 24 to 72 h exposure to 0-28.8 μM TFV or 
vehicle, phosphate buffered saline (PBS).  A parallel study was run investigating the effects of 
antioxidant pretreatment on TFV induced toxicity.  HK-2 cells were treated with N-acetyl-L-
cysteine (NAC), ascorbic acid, or resveratrol followed by 24 h exposure to 3 or 14.5 μM TFV, or 
PBS.  TFV reduced cell viability in 24-72 h as shown by MTT.   Lactate dehydrogenase (LDH) 
was released into the media following 24 h exposure to 14.5 and 28.8 μM TFV. TFV increased 
the oxidative stress biomarker of protein carbonylation in the mitochondrial subcellular fraction 
relative to control following TFV exposure. Manganese superoxide dismutase (MnSOD) and 
cytochrome c were released into the cytosolic subcellular fraction relative to control following 
TFV exposure.  Mitochondrial function was assessed using Seahorse XFp assays; TFV reduced 
basal and uncoupled cellular respiration when compared to vehicle at 24-72 h, but did not alter 
spare respiratory capacity.  Pretreatment with NAC, ascorbic acid, or resveratrol reduced TFV 
toxicity in HK-2 cells.   These studies suggest that TFV induces necrotic cell death at 24-48 h, 
causes oxidative damage to the mitochondria leading to increased membrane permeability, and 
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alters mitochondrial function.  Damage from oxidative stress may be an important factor in the 
mechanism of TFV induced cytotoxicity, as toxicity was prevented using an antioxidant 
pretreatment.   
Introduction 
Tenofovir disoproxil fumarate (TDF) is an antiretroviral agent that is approved in the 
United States to treat Human Immunodeficiency Virus (HIV) and chronic Hepatitis B (HBV).  
Tenofovir (TFV) is a nucleotide analogue of adenosine 5’-monophosphate that competes for 
incorporation into the growing viral strand during chain elongation and blocks reverse 
transcriptase, leading to chain termination (Balzarini et al., 1993; Robbins et al., 1998).  To 
improve its oral bioavailability, it is administered as the prodrug TDF, which is deesterified 
intracellularly to active TFV (Choi et al., 2008; Shaw et al., 1997).  Its long half-life provides for 
once a day dosing, which is beneficial for compliance (Barditch-Crovo et al., 2001; Deeks et al., 
1998; Durand-Gasselin et al., 2009).  TFV is also effective in patients who have resistant HIV-1, 
making it an essential drug in the treatment of HIV according to the World Health Organization 
(Miller et al., 2001; Squires et al., 2003).   
While TFV has many positive attributes, renal toxicity remains an adverse effect 
associated with clinical use. TFV can induce increases in serum creatinine levels and higher 
plasma vitamin D binding, decreases in glomerular filtration rate (GFR) and free calcitriol, 
Fanconi Syndrome, and renal failure (Del Palacio et al., 2012; Hall et al., 2011; Havens et al., 
2013).  Fanconi syndrome is a disorder of renal tubular function that results in excess excretion 
of potassium, phosphate salts, protein, urate, and glucose.  Clinical studies indicate that the 
mitochondria of the proximal tubules are the target of TFV induced toxicity as shown by 
enlarged and malformed mitochondria in electron microscopy cross sections (Cote et al., 2006; 
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Hall et al., 2011; Herlitz et al., 2010; Woodward et al., 2009).  Proximal tubular mitochondrial 
toxicity has also been described in mice and rats treated with TFV as shown by disruptions in 
mitochondrial cristae and a reduction in mtDNA levels (Kohler et al., 2009; Lebrecht et al., 
2009).      
Though TFV induced renal toxicity has been documented, very little is known about the 
mechanism; this knowledge gap may be due in part to limited experimental models. In vitro 
studies have used primary renal proximal tubule cells treated for up to 22 days and in vivo mice 
and rat models were treated with oral gavage for 5-8 weeks (Kohler et al., 2009; Lebrecht et al., 
2009; Vidal et al., 2006; Wang & Flint, 2013).  The duration of these experiments can hamper 
mechanistic studies, and the added stress of daily oral gavage can complicate mechanistic studies 
using animal models.  Cell lines with better responsiveness to TFV could circumvent these 
issues.   
In our previous study, our laboratory reported that Human Kidney-2 cells (HK-2) were a 
suitable model to study TFV induced renal cytotoxicity.  HK-2 cells retain similar activity and 
biochemical properties to in vivo cells and are commonly used in renal mechanistic studies 
(Gunness et al., 2010; Miyamoto et al., 2012; Paolicchi et al., 2003; Ryan et al., 1994).  Using 
clinically relevant concentrations, we determined that TFV causes oxidative stress, reduced 
cellular ATP levels, and induced apoptosis within 72 h (Murphy, Stafford, Petrasovits, Boone, & 
Valentovic, 2017).  The purpose of this study was to further establish the mechanism of TFV 
induced renal cytotoxicity as well as to begin preliminary tests on toxicity prevention.  
In this manuscript, we demonstrate that TFV causes lactate dehydrogenase (LDH) 
leakage and reduces mitochondrial function via oxidative stress and loss of membrane integrity.  
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Additionally, our studies showed that TFV cytotoxicity may be prevented or mitigated using 
antioxidant pretreatment.   
Methods  
Chemicals and Reagents  
TFV was purchased from Cayman Chemicals (Item No. 13874, Ann Arbor, MI) and was 
used for all studies.  The cell treatment vehicle was phosphate buffered saline (Invitrogen, 
Carlsbad, CA, Item No. 14175095).  Resveratrol, N-acetyl-L-cysteine (NAC) and other 
chemicals were purchased from Sigma Aldrich (St. Louis, MO) or Fisher Scientific (Pittsburg, 
PA).  Antibodies and kits were purchased as indicated in the sections below.     
Cell Lines and Tenofovir Treatment  
Human immortalized epithelial HK-2 cells were purchased from the American Type 
Culture Collection (ATCC) and were cultured according to ATCC guidelines. In brief, cells were 
grown in a keratinocyte-free media with 50 µg/ml bovine pituitary extract and 5ng/ml 
recombinant epithelial growth factor from Invitrogen (Carlsbad, CA, Item No. 17005-04) in a 
warm humidified incubator with constant settings of 37
o
C and 5% CO2.  HK-2 cells were plated 
into six-well tissue culture plates (Corning, Sigma Aldrich Item No. CLS3516), 75 ml tissue 
culture flasks (USA Scientific, Item No. CC7682-7506) or T75 tissue culture flasks (USA 
Scientific, Item No. CC7682-4175) at a concentration of 750,000 cells/ml and allowed to grow 
for 48 h.  Media was replaced and cells were treated with a final concentration of 0, 14.5, or 28.8 
uM TFV for 24, 48, or 72 h. The vehicle was an equal volume of phosphate buffered saline 
(PBS).   Following each treatment period, cells were collected with Trypsin-EDTA (0.25%) 
(Invitrogen, Item No. 25200072) for sample analysis. 
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Cell Viability  
Cells were plated into 48-well tissue culture plates (39, 000 cells/ml) and allowed to grow 
for 48 h followed by treatment with vehicle or TFV.  Following the treatment period, cell 
viability was assessed using the MTT assay (Humphrey et al., 2005).  This assay relies on the 
conversion of tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) to formazan by NAD(P)H-dependent oxidoreductases.  
When cells lose membrane integrity as necrosis develops following exposure to a 
toxicant, LDH is released from the cell into the extracellular space.  This leakage can be used as 
a quantification of cell death via necrosis.  Western blot analysis was used to evaluate LDH 
leakage from HK-2 cells into the media.  Following the 24-48 h treatment period with vehicle or 
TFV, cells were pelleted, rinsed with 500 µl PBS, and centrifuged.  The pellet was then disrupted 
with lysis buffer.  Media samples were centrifuged at 2,000xg for ten min to remove any cell 
debris.  Protein content was measured, and each lane was loaded with 10 µg of protein.  
Membranes were probed using a rabbit polyclonal antibody for LDH (Abcam, Item No. 
ab47010; 1:500 dilution in 5% BSA/TBST).  Results from three independent experiments were 
analyzed with BioRad Chemidoc densitometry software (version 4.0.1). 
Mitochondrial Isolation 
Following collection with Trypsin-EDTA, mitochondria were isolated using a 
Mitochondrial Isolation Kit for Cultured Cells (Thermo Scientific, Item No. 89874) and 
differential centrifugation.  Mitochondria were isolated according to the manufacturer’s 
directions, with the exception of added protease inhibitor.  Briefly, cells were centrifuged at 
850xg for ten min and resuspended in 800 μL of Reagent A with added protease inhibitor.  
Samples were vortexed for five sec at maximum speed and then incubated on ice for two min.  
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Following addition of 10 μL of Reagent B, samples were vortexed for five sec at maximum 
speed and incubated on ice for ten minutes, vortexing every minute.  Next, 800 μL of Reagent C 
with added protease inhibitor was added and the samples were centrifuged at 750xg for ten min.  
The supernatant was transferred to new sample tubes and centrifuged at 12,000xg for 15 min at 
4
o
C.  The supernatant (cytosolic fraction) was transferred to a new tube and the pellet 
(mitochondrial fraction) was resuspended in 75 μL cell lysis buffer.     
Oxyblot and Western Blot  
Western blot analysis was conducted to assess protein expression of manganese 
superoxide dismutase (MnSOD), ATP Synthase, and cytochrome c in mitochondrial and 
cytosolic subcellular fractions.  Protein concentration in each sample was determined using the 
Bradford protein assay (Bradford, 1976).  A 40 μg aliquot of each sample was boiled for five min 
to denature it.  Proteins were then separated on a 12.5% polyacrylamide gel and transferred to a 
nitrocellulose membrane (Bio-Rad, Item No. 1620097); successful transfer and protein loading 
were verified using Memcode Reversible Protein Stain Kit (Pierce Biotechnology, Fisher 
Scientific, Item No. PI-24580).  Membranes were blocked using either a 5% w/v milk/TBST 
solution (10mM Tris-HCl, 150mM NaCl, 0.1% Tween-20; pH 8.0) or a 3% Bovine Serum 
Albumin (BSA)/PBST solution for one h.  Membranes were next incubated with continual 
shaking overnight at 4
o
C with a rabbit polyclonal antibody for MnSOD (Abcam, Item No. 
ab13534, 1:500 dilution), ATP Synthase (1:1000 dilution) (Cell Signaling Technology, Item No. 
9502) or cytochrome c (Cell Signaling, Item No. 4272, 1:1000 dilution).  The membranes were 
washed four times with TBST and goat anti-rabbit HRP-linked secondary antibodies (Santa Cruz 
Biotechnology, Item No. sc-2030, 1:5000 dilution in 5% milk/TBST) and added for one h. 
Membranes were washed again with TBST and then developed using Amersham ECL Western 
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Blotting Detection Agent (GE Healthcare Life Sciences, Item No. RPN2232).  A BioRad 
chemic-doc system was used to capture the gel image and used for densitometry analysis.  All 
western analyses were conducted as three independent experiments. Western blot was also 
conducted as described above using two mouse polyclonal antibodies, cytochrome c oxidase IV 
(COX-IV, Abcam, Item No. ab14744) and cytochrome c oxidase subunit 1 (MtCO-1, Abcam, 
Item No. 14705).  COX-IV was diluted 1:1000 in 5% w/v milk/TBST and MtCO-1 was diluted 
1:2000 in 3% w/v milk/TBST.  Following washing with TBST, membranes were treated with a 
goat anti-mouse HRP-linked secondary antibody for one h (Santa Cruz Biotechnology, Item No. 
sc-2005).  Membranes were washed and developed as described previously.   
There are several markers of oxidative stress, including protein carbonylation, which can 
produce an aldehyde or ketone side chain on cellular proteins.  Protein carbonylation was 
analyzed using the Oxyblot Protein Oxidation Detection Kit (EMD Millipore, Item No. S7150).  
A 25 μg aliquot of sample was derivatized as previously described and protein loading was 
verified using the MemCode Protein Stain (Terneus et al., 2007). Briefly, protein carbonyl 
moieties on cellular proteins generated by oxidative stress are derivatized in the presence of 2,4-
dinitrophenylhydrazine (DNPH) to stable 2,4-dinitrophenylhydrazone groups; the primary 
antibody (1:150 dilution in 1% BSA/PBST) recognizes these 2,4-dinitrophenylhydrazone groups 
on proteins.  Results from three independent experiments were analyzed with BioRad Chemidoc 
densitometry software (version 4.0.1, Catalog No. 170-9690, BioRad, Hercules, CA, USA).  
Seahorse XFp Assays  
Seahorse XFp Assays allow measurement of basal Oxygen Consumption Rate (OCR) and 
Extracellular Acidification Rate (ECAR), as well as following injection of compounds to identify 
sources of mitochondrial impairment.  Mitochondrial function was measured using Agilent Cell 
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Phenotype, Mitochondrial Stress, and Glycolytic Stress Assays following optimization of cell 
number per well.  
Briefly, cells were cultured in XFp Culture Miniplates (25,000 cells/ml) (Agilent 
Technologies, Item No. 103025-100) and allowed to grow for 48 h followed by treatment with 
vehicle or TFV.  Prior to the assay, cells were washed with assay media (Agilent Technologies, 
Item No. 103334-100) supplemented with 1 mM pyruvate, 2 mM glutamine, and 0 mM glucose 
and equilibrated in 180 μL pre-warmed assay media at 37oC with no CO2 for one h.  In each 
assay, three basal OCR/ECAR measurements were taken at seven minute intervals using the 
Seahorse XFp instrument system.  Following basal measurements, various probes were injected 
and additional OCR and ECAR measurements were taken. Maximal respiration was stimulated 
by the addition of Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) an uncoupler 
of mitochondrial function.  In the Cell Phenotype Assay, stressor mix was injected at 
approximately minute 15 (50 μM FCCP/50 μM oligomycin) to uncouple the electron transport 
chain (Agilent Technologies, Item No. 103275-100) and OCR and ECAR were measured in six 
minute intervals.  In the Mitochondrial Stress Test (Agilent Technologies, Item No. 103015-
100), injections of oligomycin (0.5 µM), FCCP (0.5 μM), and a mixture of Rotenone/Antimycin 
A (0.5 μM) were added and OCR and ECAR were measured.  Preliminary studies optimized the 
FCCP concentration to 0.5 μM. In the Glycolysis Stress Test (Agilent Technologies, Item No. 
103020-100), glucose (10 mM), oligomycin (1 µM), and 2-DG (50 mM) were injected and OCR 
and ECAR were measured.   
Following each assay, cells were washed with 200 μL PBS and lysed.  Protein 
concentration was assessed using the Bradford Assay as previously described (Bradford, 1976).  
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Results were normalized to total protein concentration and analyzed using Wave Software 
(Agilent Technologies, Wave for Desktop, Version 2.3.0.19).          
Antioxidant Protection Studies  
A separate series of experiments evaluated whether various antioxidants could provide 
protection from TFV. HK-2 cells were allowed to grow for 48 h followed by a one h 
pretreatment with resveratrol (5, 7.5, or 10 µM in DMSO), N-acetyl-L-cysteine (NAC, 0.5 or 1 
mM in sterile water), or ascorbic acid (10 or 25 μM in sterile water) followed by a 24 h 
incubation with 0, 3, or 14.5 μM TFV. Viability of cells was assessed using the MTT assay. All 
media and MTT were removed from the cells prior to the addition of DMSO to prevent any 
interaction of antioxidants with formazan.  
Statistical Analysis  
Data are presented as Mean ± SEM with 2–4 independent experiments with 2–4 
biological replicates. Differences between groups were determined with a one-way ANOVA 
followed by a Holm–Sidak post-hoc test with p < 0.05 (SigmaStat, SSPS). 
Results  
TFV Effects on Cell Viability  
TFV was cytotoxic to HK-2 cells as cell viability was diminished within 24 h when 
compared to vehicle based on the MTT assay.  TFV reduced cell viability at 24 h (p<0.001) at 
both concentrations tested (Figure 12).  Cell Viability continued to be diminished at 48 and 72 h, 
with 28.8 μM TFV showing additional decline in viability (p<0.05).     
In our previous study, we determined that TFV initiates apoptosis at 72 h, but not at 24 or 
48 h.  Western blot was run on tissue and media samples treated with TFV to determine if 
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multiple mechanisms of toxicity occur.  LDH leakage from tissue into media was increased at 24 
and 48 h (p<0.01) but not at 72 h (Figure 13).  This leakage is indicative of necrosis.   
  
Figure 12. TFV cytotoxic effects on HK-2 cell viability using MTT.  Tenofovir decreased cell 
viability at 24 (A), 48 (B), and 72 h (C). Different superscript letters (a-c) indicate difference 
between treatment groups (p<0.05) at the designated time period.  D) Depicts cell viability 
following 72 h exposure to tenofovir in experiments where mitochondria were isolated to ensure 
treatment success.  Each bar represents Mean ± SEM for four independent experiments run with 
three biological replicates.   
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Figure 13.  LDH expression in HK-2 cell lysate and media following tenofovir (TFV) 
exposure.  LDH release into media (M) and HK-2 cell lysate (T) expressed as percent of control 
following 24 (A) and 48 h (B) exposure to TFV.  LDH release into the media was increased 
(p<0.01) relative to control at all concentrations and time points.  Different superscripts (a-c) 
indicate differences between treatment groups at designated time periods. C) and D) depict 
densitometry and representative blots for 10 µg protein loading of cell lysates and media samples 
for 24 (C) and 48 h (D) TFV exposure visualized with Memcode Reversible Protein Staining.    
Each bar represents Mean ± SEM for two independent experiments run with three biological 
replicates.     
 
TFV Effects on Mitochondrial Stress and Membrane Integrity  
Mitochondrial oxidative stress was induced by 28.8 μM TFV relative to control at 72 h 
(p<0.05) as shown by Oxyblot analysis (Figure 14).  Protein carbonylation was not increased in 
the cytosolic fraction relative to control.  A 72 h exposure to TFV also caused leakage of 
MnSOD from mitochondria to the cytosol relative to control (p<0.001, Figure 14).  Loss of this 
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enzyme within the mitochondrial antioxidant system may further contribute to the observed 
oxidative damage.   
TFV alters mitochondrial membrane integrity as shown by MnSOD leakage (Figure 14).  
Additional studies on mitochondrial proteins were conducted to assess the extent of 
mitochondrial membrane damage.  TFV caused leakage of cytochrome c from the mitochondria 
to the cytosol relative to control (p<0.001) as shown by western blot (Figure 15).  However, TFV 
did not induce leakage of ATP Synthase into the cytosol (Figure 15).  The observed difference 
may be due to localization of proteins within the mitochondria.  ATP synthase is located in the 
inner mitochondrial membrane while cytochrome c is located in the intermitochondrial space.  
   
63 
 
Figure 14. Tenofovir (TFV) treatment of HK-2 cells for 72 h increases protein 
carbonylation and induces leakage of manganese superoxide dismutase (MnSOD).  A) 
Protein carbonylation in HK-2 mitochondrial and cytosolic fractions following 72 h exposure to 
28.8 µM TFV.  B) MnSOD expression in mitochondrial and cytosolic fractions following 72 h 
exposure to 28.8 μM TFV.  C) and D) depict densitometry and representative blots for 25 µg (C) 
and 40 µg (D) protein loading of cytosolic and mitochondrial fractions of cell lysates for 72 h 
TFV exposure visualized with Memcode Reversible Protein Staining.  Asterisks represent 
differences between groups (*p<0.05, ***p<0.001).  Each bar represents Mean ± SEM for three 
independent experiments run with three biological replicates. 
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Figure 15. Tenofovir (TFV) alters mitochondrial membrane integrity.  A) Expression of 
cytochrome c in mitochondrial and cytosolic fractions of cell lysate following 72 h exposure to 
28.8 μM TFV.  B) Expression of ATP Synthase in mitochondrial and cytosolic fractions of cell 
lysate following 72 h exposure to 28.8 µM TFV.  C) and D) depict densitometry and 
representative blots for 40 µg protein loading of cytosolic and mitochondrial fractions of cell 
lysates for 72 h TFV exposure visualized with Memcode Reversible Protein Staining.  Asterisks 
represent differences between groups (***p<0.001).  Each bar represents Mean ± SEM for three 
independent experiments run with three biological replicates. 
    
 TFV Effects on Mitochondrial DNA  
There are conflicting reports on whether TFV inhibits mitochondrial DNA replication, as 
some studies have reported TFV is a weak inhibitor of DNA Polymerase γ (Pol γ).  We assessed 
this effect in our cell model via expression of cytochrome c oxidase subunits following 72 h 
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exposure to TFV.  TFV did not alter the expression or localization of the nuclear-encoded 
subunit, COX-IV, or the mitochondrial-encoded subunit, MtCO-1 (Figure 16).  These data 
indicate that 28.8 μM TFV does not affect mitochondrial DNA replication under the 
experimental conditions of 72 h exposure.   
   
Figure 16. TFV does not alter expression or localization of subunits of cytochrome c 
oxidase.  A)  Expression of nuclear-encoded subunit, COX-IV, in mitochondrial and cytosolic 
fractions of cell lysate following 72 h exposure to 28.8 μM TFV.  B) Expression of 
mitochondrial-encoded subunit, MtCO-1, in mitochondrial and cytosolic fractions of cell lysate 
following 72 h exposure to 28.8 μM TFV.  C) and D) depict densitometry and representative 
blots for 40 μg protein loading of cytosolic and mitochondrial fractions of cell lysates for 72 h 
TFV exposure visualized with Memcode Reversible Protein Staining.  Each bar represents Mean 
± SEM for three independent experiments run with three biological replicates. 
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TFV Effects on Mitochondrial Function  
Mitochondrial function was assessed using a Seahorse XFp instrument.  In the cell 
phenotype assay, basal oxygen consumption rate (OCR) was reduced by 27% and basal 
extracellular acidification rate (ECAR) was reduced by 16% at 72 h exposure to TFV when 
compared to vehicle (p<0.05) (Figure 19); however, basal OCR and ECAR were similar to 
control at 24 and 48 h TFV exposure (Figure 17, Figure 18).  The addition of FCCP and 
oligomycin uncouples the electron transport chain and inhibits ATP synthase, respectively, 
causing a compensatory increase in glycolysis and OCR to try to restore membrane potential and 
meet energy demands.  At 24-72 h exposure to TFV, stressed OCR were reduced relative to 
control at all concentrations tested (p<0.05, Figure 17, Figure 18, Figure 19).  Stressed ECAR 
was reduced at 72 h exposure (p<0.05, Figure 19) but not at 24 or 48 h exposure (Figure 17, 
Figure 18).      
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Figure 17. Cell Phenotype Assay, oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR) following 24 h TFV exposure.  A)  Basal vs. stressed OCR 
following 24 h exposure to TFV.  B) Time course graph of OCR in the cell phenotype assay 
following 24 h TFV exposure.  C) Basal vs. stressed ECAR following 24 h TFV exposure.  
Different superscripts (a-d) represent differences between groups (p<0.05).  D)  Time course 
graph of ECAR in the cell phenotype assay following 24 h TFV exposure.  Bar graphs are 
presented as Mean ± SEM for four independent experiments run with two biological replicates. 
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Figure 18. Cell Phenotype Assay, oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR) following 48 h TFV exposure.  A)  Basal vs. stressed OCR 
following 48 h exposure to TFV.  B) Time course graph of OCR in the cell phenotype assay 
following 24 h TFV exposure.  C) Basal vs. stressed ECAR following 48 h TFV exposure.  
Different superscripts (a-d) represent differences between groups (p<0.05).  D)  Time course 
graph of ECAR in the cell phenotype assay following 48 h TFV exposure.  Bar graphs express 
data as Mean ± SEM for four independent experiments run with two biological replicates. 
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Figure 19. Cell Phenotype Assay, oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR) following 72 h TFV exposure.  A)  Basal vs. stressed OCR 
following 72 h exposure to TFV.  B) Time course graph of OCR in the cell phenotype assay 
following 72 h TFV exposure.  C) Basal vs. stressed ECAR following 24 h TFV exposure.  
Different superscripts (a-d) represent differences between groups (p<0.05).  D)  Time course 
graph of ECAR in the cell phenotype assay following 72 h TFV exposure.  Bar graph values 
expressed as Mean ± SEM for four independent experiments run with two biological replicates. 
 
A mitochondrial stress test was run following 24-72 h TFV exposure to further explore 
the observed reduction in stressed OCR in the cell phenotype assay.  In this assay, probes are 
serially injected to reveal key parameters of mitochondrial function.  Oligomycin inhibits ATP 
synthase and the resulting decrease in OCR correlates to mitochondrial respiration linked to ATP 
production.  FCCP is an uncoupling agent that increases oxygen consumption to maximal levels, 
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which can be used to calculate spare respiratory capacity.  The final injection of antimycin 
A/rotenone inhibits complex I and III, allowing for calculation of non-mitochondrial respiration.   
Exposure to 14.5 and 28.8 μM TFV caused a decrease in basal (p<0.001) and maximal 
(p<0.05) OCR at 72 h exposure, but not at 24-48 h (Figure 20, Figure 21, Figure 22).  ATP 
production was also decreased at 72 h following exposure to 28.8uM TFV (p<0.05, Figure 22) 
but not at 24-48 h (Figure 20, Figure 21).  Spare respiratory capacity was not affected at any time 
point or concentration tested (Figure 20, Figure 21, Figure 22).   
 
Figure 20. Mitochondrial Stress Test, effects of TFV on ATP production and mitochondrial 
respiratory capacity.  Basal (A) and Maximal (B) OCR following 24 h exposure to TFV.  C)  
Spare respiratory capacity following 24 h TFV exposure.  D)  Time course graph of OCR in the 
mitochondrial stress test following 24 h TFV exposure.  Bar graph values represent  Mean ± 
SEM for four independent experiments run with two biological replicates. 
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Figure 21. Mitochondrial Stress Test, effects of TFV on ATP production and mitochondrial 
respiratory capacity.  Basal (A) and Maximal (B) OCR following 48 h exposure to TFV.  C)  
Spare respiratory capacity following 48 h TFV exposure.  D)  Time course graph of OCR in the 
mitochondrial stress test following 48 h TFV exposure.  Bar graph values are presented as Mean 
± SEM for four independent experiments run with two biological replicates. 
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Figure 22. Mitochondrial Stress Test, effects of TFV on ATP production and mitochondrial 
respiratory capacity.  Basal (A) and Maximal (B) OCR following 72 h exposure to TFV.  C)  
Spare respiratory capacity following 72 h TFV exposure.  Asterisks indicate differences between 
groups (*p<0.05, **p<0.01).  D)  Time course graph of OCR in the mitochondrial stress test 
following 72 h TFV exposure.  Bar graph values are presented as Mean ± SEM for four 
independent experiments run with two biological replicates. 
 
Based on the ECAR results in the cell phenotype assay, glycolytic stress tests were run at 
72 h TFV exposure to further elucidate the effect of TFV on glycolysis.  Cells are saturated with 
glucose, and basal ECAR was assessed.  Oligomycin is then injected to inhibit ATP synthase and 
drive glycolysis to maximal capacity.  Finally, 2-DG, a glucose analog, is injected to inhibit the 
first enzyme in the glycolytic pathway, hexokinase; the resultant decrease in ECAR ensures that 
the ECAR produced in the experiment is due to glycolysis.  TFV exposure had no effect on any 
measured glycolytic parameters (Figure 23).   
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Figure 23. Glycolytic Stress Test, effects of TFV on glycolytic capacity and reserve.  Basal 
(A) and Maximal (B) ECAR following 72 h exposure to TFV.  C)  Spare glycolytic capacity 
following 72 h TFV exposure.  D)  Glycolytic reserve following 72 h exposure to TFV.  E)  
Time course graph of OCR in the glycolytic stress test following 72 h TFV exposure.  Bar graph 
values are presented as Mean ± SEM for four independent experiments run with two biological 
replicates. 
 
Antioxidant Protection of TFV Cytotoxicity  
Our previous study showed that oxidative stress was increased by TFV resulting in 
increased protein carbonylation and 4-hydroxynonenol (4-HNE) adduct formation, suggesting 
that a rise in reactive oxygen species occurs with TFV cytotoxicity.  Pretreatment with ascorbic 
acid, resveratrol, and N-acetyl-L-cysteine (NAC) reduced TFV toxicity in HK-2 cells; cell 
viability was higher in cells exposed to TFV in the presence of antioxidants compared to TFV 
alone (Figure 24, Figure 25, and Figure 26).  While 0.5 mM NAC did protect from TFV 
cytotoxicity, it did not provide enough protection to return viability to the same level as control 
(Figure 24).  Additionally, 25 μM ascorbic acid did protect from 14.5 μM TFV cytotoxicity, but 
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it did not provide enough protection to return viability to the same level as control (Figure 25).  
These findings suggest that use of an antioxidant pretreatment can reduce TFV cytotoxicity in 
HK-2 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Effects of N-acetyl-L-cysteine (NAC) pretreatment on TFV cytotoxicity. N-
acetyl-L-cysteine (NAC) protected HK-2 cells from tenofovir cytotoxicity as assessed by MTT 
viability. Cells were treated with 0 (−), 0.5 mM (+), or 1 mM (+) NAC followed by a 24 h 
exposure to 0 (−), 3 μM (+) or 14.5 µM (+) TFV.  Different superscript letters (a-d) indicate 
statistical difference from all other groups (p<0.05). Values represent Mean ± SEM for three 
independent experiments run with three biological replicates. 
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Figure 25. Effects of ascorbic acid (Asc) pretreatment on TFV cytotoxicity. Asc protected 
HK-2 cells from tenofovir cytotoxicity as assessed by MTT viability. Cells were treated with 0 
(−),  10 μM (+), or 25 μM (+) Asc followed by a 24 h exposure to 0 (−), 3 μM (+) or 14.5 µM (+) 
TFV.  Different superscript letters (a-c) indicate statistical difference from all other groups 
(p<0.05). Values represent Mean ± SEM for three independent experiments completed after 
publication of the previous study  run with three biological replicates.  
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Figure 26. Effects of resveratrol (Res) pretreatment on TFV cytotoxicity. Res protected HK-
2 cells from tenofovir cytotoxicity as assessed by MTT viability. Cells were treated with 0 (−),  5 
μM (+), 7.5 μM (+), or 10 μM (+) Asc followed by a 24 h exposure to 0 (−), 3 μM (+) or 14.5 
µM (+) TFV.  Different superscript letters (a-b) indicate statistical difference from all other 
groups (p<0.05). Values represent Mean ± SEM for three independent experiments run with 
three biological replicates. 
 
Discussion  
TFV is a very effective antiviral nucleotide reverse transcriptase inhibitor prescribed 
worldwide in the treatment of HIV and Hepatitis B.  Unfortunately, patients treated with TFV 
have an increased incidence of renal impairment (Fux et al., 2007; Verhelst et al., 2002). Renal 
TFV toxicity in humans is characterized by Fanconi Syndrome and development of irreversible 
impaired renal function depending on the dose. There is a positive correlation between increased 
TFV plasma concentration, renal toxicity and the duration that patients were treated with TFV 
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(Ezinga et al., 2014; Quesada et al., 2015).  Examination of the mechanism of TFV induced renal 
toxicity is clinically relevant because HIV treatment is chronic. Understanding the mechanism of 
TFV nephrotoxicity is essential for the development of methods to mitigate TFV renal 
impairment. 
 Our current studies further probed TFV renal cytotoxicity in HK-2 cells, which are an 
effective model for examining TFV nephrotoxicity.  In a previously published paper, we showed 
that treatment with clinically relevant concentrations of TFV reduced cell viability in HK-2 cells 
within 24 h.  We also showed that TFV increased protein carbonylation and 4-HNE adduct 
formation in whole cell lysate at 72 h exposure and induced apoptosis via activation of caspase 3 
and 9.  There is also marked reduction in intracellular ATP at 72 h, but not 24 or 48 h TFV 
exposure (Murphy et al., 2017).  These data provide insight into the mechanism of TFV induced 
cytotoxicity, but also leave many questions.   
 Our previous study (Murphy et al., 2017) supported the hypothesis that mitochondrial 
damage and oxidative stress play a role in TFV induced cytotoxicity; the current study further 
probed this mechanism.  While TFV induced apoptosis at 72 h exposure as shown by caspase 3 
and 9 cleavage, activation of these proteins was not observed at lower time points.  Additionally, 
intracellular ATP was not affected until 72 h exposure, indicating that multiple mechanisms of 
toxicity may be involved.  When cells undergo necrosis, organelles swell and break down, 
leading to disruption of plasma membrane integrity (Challa & Chan, 2010; Moquin & Chan, 
2010; Schweichel & Merker, 1973).  This loss in membrane integrity leads to the release of 
intracellular contents. LDH is a stable enzyme that is expressed in every cell type; it is 
commonly used as a marker of necrosis (Burd & Usategui-Gomez, 1973; Chan, Moriwaki, & De 
Rosa, 2013).  Our study showed an increase in LDH release from HK-2 cells into the media 
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following 24 and 48 h exposure to TFV (Figure 13), indicating that TFV induces necrosis in HK-
2 cells within 24 h exposure.  These findings are in line with clinical data of patients with TDF 
induced renal injury, which show marked tubular necrosis (Herlitz et al., 2010). 
 The results of our previous study also indicated that the mitochondria are the target of 
TFV renal cytotoxicity.  Clinical studies found that the mitochondria of the proximal tubules are 
the target of TFV induced toxicity as shown by enlarged and malformed mitochondria in electron 
microscopy cross sections from patients taking 300 mg TDF for approximately seven years (Cote 
et al., 2006; Hall et al., 2011; Herlitz et al., 2010; Woodward et al., 2009).  Cytochrome c 
excretion into urine is observed clinically in HIV patients who have developed TFV induced 
nephropathies (Maggi et al., 2012).  Proximal tubular mitochondrial toxicity has also been 
described in mice and rats treated with TFV as shown by disruptions in mitochondrial cristae and 
a reduction in mtDNA levels (Kohler et al., 2009; Lebrecht et al., 2009).  The results of our 
current study are in accordance with these findings.  TFV increased oxidative damage in the 
mitochondrial fraction of HK-2 cells, but not the cytosolic subcellular fraction (Figure 14).  
Additionally, there is a loss in mitochondrial membrane integrity, as indicated by the presence of 
cytochrome c and MnSOD in the cytosolic subcellular fraction following 72 h TFV exposure 
(Figure 14 and 15).  Release of cytochrome c to the cytosol induces apoptosis via binding to 
Apoptotic protease activating factor 1 (Apaf-1) to form an apoptotic complex that activates 
caspase 9 (Jiang & Wang, 2000; Liu, Kim, Yang, Jemmerson, & Wang, 1996).      
 Cytochrome c is a key component of the electron transport chain; cytochrome c 
mitochondrial leakage into the cytosol may contribute to the loss of cellular ATP production 
observed in our previous study.  Interestingly, analysis of ATP synthase expression showed no 
leakage into the cytosolic fraction or alteration in expression (Figure 15); ATP synthase is a 
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membrane bound protein in the inner mitochondrial membrane and membrane breakdown may 
not be severe enough to induce release of ATP synthase.  It is unlikely that loss of ATP synthase 
from the mitochondrial membrane contributes to the observed reduction in cellular ATP 
following TFV exposure.   
 MnSOD is a nuclearly encoded mitochondrial antioxidant enzyme that is essential in 
maintaining the balance of generation and detoxification of reactive oxygen species (ROS).  
MnSOD functions mainly via detoxifying superoxide free radicals that are generated during 
mitochondrial respiration.  Oxidative stress occurs when there is an imbalance between the 
generation and detoxification of ROS and reactive nitrogen species (RNS)(Fridovich, 1995).  
The role of MnSOD in toxicity development in HIV patients has not been extensively studied.  
However, one study has shown that Blood Urea Nitrogen (BUN) is elevated in wild type mice  
treated with 50 mg/kg TDF but not in transgenic mice that overexpress MnSOD (Glover et al., 
2014).  Our study shows that following 72 h exposure with 28.8 μM TFV, MnSOD leakage into 
the cytosol increased 1.5-fold (Figure 14).  This data indicates a loss in mitochondrial membrane 
integrity following TFV exposure and may indicate a decreased ability to respond to oxidative 
stress.  Whether MnSOD leakage contributes to the observed oxidative damage is not yet clear as 
there was no change in mitochondrial expression following TFV treatment.  Additional study 
needs to be conducted to determine more fully what role MnSOD plays in the development of 
TFV renal cytotoxicity.   
 TFV has been shown to be a weak inhibitor of Pol γ, but effects on mitochondrial DNA 
(mtDNA) show conflicting results, possibly due to variation between cell types.  In a clinical 
study, mtDNA was increased 1.4 fold in peripheral blood mononuclear cells (PBMCs) in HIV-1 
infected patients taking 300mg TDF daily for 96 weeks (Curran et al., 2012).  In a different study 
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using an HIV transgenic mouse model, mtDNA was elevated following five weeks of daily TDF 
treatment.  However, further investigation into this study detected diminished mtDNA by TDF 
compared to the vehicle group when laser capture microscopy was used to microdissect proximal 
tubules of HIV-1 transgenic mice (Kohler et al., 2009).  Conversely, exposing human primary 
renal proximal tubule cells to 2 and 200 uM TFV for 19 days showed no change in mtDNA 
compared to control (Wang & Flint, 2013).  However, this same study reported TFV decreased 
mtDNA in primary human adipocytes cultured for 19 days in the presence of 2 and 200 uM TDF.  
No change in mtDNA was also reported when human renal proximal tubular epithelial cells were 
incubated for 22 days with 30 uM TFV(Vidal et al., 2006).    
The results of our study indicate that TFV does not alter mitochondrial DNA (Figure 5).  
While we did not measure mtDNA directly, we assessed expression of both nuclear and 
mitochondrial-encoded subunits of cytochrome c oxidase.  TFV did not alter the expression or 
localization of the nuclear-encoded subunit, COX-IV, or the mitochondrial-encoded subunit, 
MtCO-1 (Figure 16).  While it is possible that mtDNA is affected and there is a compensatory 
increase in translation or a lower rate of enzyme turnover, our results are similar to another study 
that assessed both mtDNA and cytochrome c oxidase expression following TFV exposure.  
Rhesus monkeys, rats, and woodchucks were treated with varying doses of TDF for 56, 28, and 
90 days respectively.  Following the treatment period, cytochrome c oxidase and mtDNA levels 
were unaltered in all models and treatment groups (Biesecker et al., 2003).       
This is the first study to conduct functional studies to determine the effect of TFV on the 
mitochondria.  Using Seahorse XfP technology, we show that TFV alters mitochondrial function.  
At 24 and 48 h TFV exposure, maximal OCR is lower relative to control but basal OCR is 
unaffected (Figure 17, Figure 18).  ECAR is not affected at either time point.  However, at 72 h 
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TFV exposure, basal OCR and ECAR, and maximal OCR and ECAR are lower relative to 
control.  Upon further investigation in the mitochondrial stress test, 72 h TFV exposure results in 
lower ATP production, but does not affect spare capacity.  This decline in ATP production is not 
observed in lower time points, which is consistent with our previous study results.   
The results of our study suggest TFV induces mitochondrial changes similar to other 
mitochondrial toxicants.  One study using hepatocellular carcinoma cells to evaluate 27 
compounds found that Seahorse technology can be helpful in mitochondrial mechanistic studies.  
Compounds such as rotenone, a known complex I inhibitor, show a decrease in OCR and spare 
capacity, but an increase in ECAR.  ATP synthase inhibitors such as oligomycin, show a 
decrease in OCR with no effect on reserve capacity, while uncouplers such as 2,4-dinitrophenol 
increase OCR and ECAR with no effect on reserve capacity (Eakins et al., 2016).  These 
extracellular flux assays were able to correctly predict the mechanisms of mitochondrial toxicity 
in 76% percent of known test compounds used.  As TFV reduces OCR but does not alter spare 
capacity, it is possible that TFV inhibits ATP synthase activity; additional study needs to be done 
to determine the direct inhibitory effects of TFV.  Our studies indicated ATP synthase expression 
was not diminished by TFV.  
Eakins and associates (2016) further determined that known glycolytic inhibitors such as 
clotrimazole induce reduced OCR and reserve capacity but no effect on ECAR levels.  The 
results of our glycolytic stress test show no effect on ECAR at 72 h exposure, but there is 
reduced OCR (Figure 22); based on results of published glycolytic inhibitors, it is possible that 
TFV alters glycolysis in some way.  It remains unknown if the cause of decreased OCR and 
ECAR following TFV exposure is due to loss of mitochondrial membrane integrity, direct 
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enzyme inhibition, fewer functional mitochondria, or a combination of several factors.  Further 
studies need to probe the mechanism of mitochondrial toxicity.      
Resveratrol and ascorbic acid are widely known as antioxidants and have been shown to 
prevent renal toxicity of a number of chemotherapeutic agents that induce oxidative stress in 
vitro and in vivo rodent models, including cisplatin and cadmium (Do Amaral et al., 2008; Fu, 
Zhao, Peng, Wu, & Zhang, 2017; Koyuturk, Yanardag, Bolkent, & Tunali, 2007; Maliakel, 
Kagiya, & Nair, 2008; Valentovic et al., 2014).  N-acetyl-L-cysteine (NAC) is the precursor to 
glutathione (GSH), an important cellular antioxidant.  NAC is most notably used to treat 
acetaminophen overdose by providing cysteine for glutathione synthesis to mitigate hepatic 
toxicity, but has been shown to protect hepatocytes from oxidative damage induced by cadmium 
and mercury in rats (Joshi, Mittal, Shukla, Srivastav, & Srivastav, 2014; Wang, Zhu, Liu, & Liu, 
2014). 
  Our study shows that an hour pretreatment with resveratrol, NAC, or ascorbic acid 
protects HK-2 cell viability when exposed for 24 h to 3 or 14.5 μM TFV (Figure 17).  It should 
be noted that high concentrations of NAC (0.5-1 mM) were required to induce a protective 
effect; resveratrol may be the best choice in prevention of TFV induced cytotoxicity as it 
required the lowest concentration to induce a protective effect (5 μM).  It is unclear by what 
mechanism antioxidants protect against TFV toxicity. Our previous studies did not show markers 
of oxidative damage (protein carbonylation and 4-HNE adduct formation) until 72 h exposure, 
but protection was observed in our current study within 24 h TFV exposure.  Additional study 
needs to be done to determine the role of reactive oxygen and nitrogen species at lower time 
points as well as to elucidate the mechanism of antioxidant protection.   
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Conclusion  
This study provides additional insight into the mechanism of TFV induced renal 
cytotoxicity. TFV induces necrosis within 24 h as shown by LDH release from HK-2 cells.  
Oxidative stress is increased in mitochondria, and there is a loss of mitochondrial membrane 
integrity, resulting in the release of MnSOD and cytochrome c into the cytosol.  Cytochrome c 
release further validates that TFV induces apoptosis at 72 h exposure.  Mitochondrial function is 
also altered, as shown by changes in OCR and ECAR in Seahorse XFp Assays.  The role of 
MnSOD in TFV induced cytotoxicity remains unclear.  However, antioxidant pretreatment 
attenuates TFV induced cytotoxicity, but the mechanism by which this occurs is unknown at this 
time.  Additional studies need to be conducted to determine to what degree TFV modulates 
mitochondrial function and the mitochondrial antioxidant system, as well as investigate the 
mechanism by which antioxidants protect against TFV induced oxidative damage. 
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CHAPTER 5 
SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS 
 At the end of my dissertation research, this project remains as exciting and fascinating as 
it was when I came across it in my first year communications class.  TDF is one of the most 
widely prescribed drugs to treat HIV and it is effective in patients who have resistant HIV-1.  As 
resistance to HAART can be acquired and transmitted, medications with low resistance profiles 
are key in successful treatment of HIV.  This low resistance profile makes the renal toxicity 
associated with TFV use particularly relevant.  The goal of my work was to determine the 
mechanism of TFV induced nephrotoxicity and to investigate potential methods to mitigate or 
prevent said toxicity.  My work provides insight into this mechanism as well as evidence that 
antioxidant pretreatment mitigates this toxicity; this evidence warrants further study and has 
potential clinical implications.   
HK-2 Cells are a Suitable Model to Study TFV Cytotoxicity  
One of the primary reasons that there is a knowledge gap regarding the mechanism of 
TFV toxicity is a lack of suitable experimental models; mechanistic studies require a model that 
is consistent with what occurs in humans. The selection of suitable models to study TFV 
cytotoxicity has been problematic to date.  For example, most in vivo models require subchronic 
treatment of animals. TFV toxicity in rodents such as rats has required eight weeks of daily 
treatment in order to develop nephrotoxicity (Lebrecht et al., 2009). In this study, rats treated for 
eight weeks showed declined renal function and proximal tubular damage along with enlarged 
mitochondria. Another study showed that treatment for five weeks with TFV induced oxidative 
stress in Wistar rats.  However, they were dosed with very high concentrations of TFV (Abraham 
et al., 2013).     
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An in vitro model was first reported by Wang and Flint that developed TFV cytotoxicity 
using primary human kidney cells (Wang & Flint, 2013). Primary human kidney cells required 
culturing for 19 days with 200 μM TFV to induce cytotoxicity, which was much longer and at 
concentrations higher than pharmacological levels. The need for higher concentrations of TFV to 
induce toxicity in primary proximal tubule cell lines may be due to differences in OAT1 and 
OAT3 expression. Endogenous expression of OAT1 and OAT3 in primary human proximal 
tubule cells has been shown to vary greatly from sample to sample (Lash et al., 2006) and TFV-
induced cytotoxicity is dependent on OAT1 and OAT3 expression (Kohler et al., 2011; Nieskens 
et al., 2016).  Other cell types such as HEK293 cells have been used to study tenofovir 
cytotoxicity, but appear less sensitive than our HK-2 model. One study showed that TFV-
induced cytotoxicity within 48 h in HEK293 cells transfected with OAT1; however, the IC50 was 
reported to be 316 μM (Zhang et al., 2015). 
Our HK-2 cell model is more sensitive than human primary proximal tubule cells and 
HEK293 cells as we have shown induction of cytotoxicity in 24 h compared to 22 days and at a 
concentration almost ten times lower than previously reported for human primary proximal 
tubular epithelial cells and almost 12 times lower than previously reported for HEK293 cells 
(Vidal et al., 2006; Zhang et al., 2015). In addition to inducing cytotoxicity at 24 h, our HK-2 
cell model has an IC50 of 9.2 μM TFV at 48 h, and an IC50 of 2.77 μM TFV at 72 h compared to 
an IC50 at 48 h of 316uM (Zhang et al., 2015).  
In our study, cell viability was diminished in HK-2 cells with TFV concentrations 
ranging from 1.5 to 28.8 μM. These concentrations are clinically relevant as plasma TFV 
concentrations have been reported to be 2.2 μM in HIV-1 infected patients (Barditch-Crovo et 
al., 2001; Zhang et al., 2015). As described in Chapter 1, TFV plasma concentrations are higher 
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in HIV-1 patients with existing renal insufficiency and patients with renal insufficiency also 
experience a longer duration of TFV exposure, as shown by a 15-fold increase in AUC0–24 h 
(Custodio et al., 2016; Ezinga et al., 2014; Sentenac et al., 2003). Therefore, HK-2 cells provide 
a model that can be used to examine the mechanism of toxicity without the compounding 
physiological parameters influencing the response of the kidney to a toxicant. Our studies further 
showed that HK-2 cells can differentiate the toxicity of different antiviral agents as abacavir, an 
agent that is considered less toxic to the kidney which was not toxic in our system (Figure 4D, 
Chapter 2).  
TFV Causes Oxidative Stress and Alters Mitochondrial Integrity in HK-2 Cells 
 In our study, we first probed whole cell lysate for markers of oxidative damage, protein 
carbonylation, and 4-HNE adduct formation.  Oxidative damage occurs following periods of 
oxidative stress, an imbalance between the generation and detoxification of ROS and reactive 
nitrogen species (RNS) (Fridovich, 1995).  The HK-2 cells were more sensitive to TFV and 
displayed increased oxidative stress at clinically relevant concentrations as compared to 
previously examined models. A five week treatment of rats with 12 times higher dose than what 
is clinically used reported a 25% increase in renal protein carbonylation (Abraham et al., 2013); 
the HK-2 cells demonstrated a much greater increase in protein carbonylation within a shorter 
time period than reported in vivo treatment of rats (Figure 7, Chapter 2).  Additionally, we saw a 
large increase in 4-HNE adduct formation at 72 h exposure (Figure 8, Chapter 2), indicating that 
TFV induced oxidative stress leads to lipid peroxidation.   
We further investigated oxidative damage following TFV exposure in subcellular 
fractions.  Clinical studies show that the mitochondria of the proximal tubules are the target of 
TFV induced toxicity as shown by enlarged and malformed mitochondria in electron microscopy 
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cross sections from patients taking 300 mg TDF for approximately seven years (Cote et al., 
2006; Hall et al., 2011; Herlitz et al., 2010; Woodward et al., 2009).  Cytochrome c excretion 
into urine is observed clinically in HIV patients who have developed TFV induced nephropathies 
(Maggi et al., 2012).  Proximal tubular mitochondrial toxicity has also been described in mice 
and rats treated with TFV as shown by disruptions in mitochondrial cristae and a reduction in 
mtDNA levels (Kohler et al., 2009; Lebrecht et al., 2009).  The results of our current study are in 
accordance with these findings. TFV increased oxidative damage in the mitochondrial fraction of 
HK-2 cells, but not the cytosolic subcellular fraction (Figure 14, Chapter 3).   
Additionally, there is a loss in mitochondrial membrane integrity, as indicated by the 
presence of cytochrome c and MnSOD in the cytosolic subcellular fraction following 72 h TFV 
exposure (Figure 14 and 15, Chapter 3).  This loss in membrane integrity may be due to the lipid 
peroxidation indicated by 4-HNE adduct formation.  Interestingly, analysis of ATP synthase 
expression showed no leakage into the cytosolic fraction or alteration in expression (Figure 15, 
Chapter 3); ATP synthase is a membrane bound protein in the inner mitochondrial membrane 
and membrane breakdown may not be severe enough to induce release of ATP synthase.   
 MnSOD is a nuclearly encoded mitochondrial antioxidant enzyme that is essential in 
maintaining the balance of generation and detoxification of reactive oxygen species (ROS).  
MnSOD functions mainly via detoxifying superoxide free radicals that are generated during 
mitochondrial respiration.  The role of MnSOD in toxicity development in HIV patients has not 
been extensively studied.  However, one study has shown that Blood Urea Nitrogen (BUN) is 
elevated in wild type mice treated with 50 mg/kg TDF but not in transgenic mice that 
overexpress MnSOD (Glover et al., 2014).  Our study shows that following 72 h exposure with 
28.8 μM TFV, MnSOD leakage into the cytosol increased 1.5-fold (Figure 3, Chapter 2).  This 
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data indicates a loss in mitochondrial membrane integrity following TFV exposure and may 
indicate a decreased ability to respond to oxidative stress.  Whether MnSOD leakage contributes 
to the observed oxidative damage is not yet clear as there was no change in mitochondrial 
expression following TFV treatment.   
TNFα is a proinflammaotry cytokine which is expressed in proximal tubular epithelial 
cells. TNFα can be secreted from cells to induce an inflammatory response as a protective 
mechanism during initial exposure to toxicants (Gu et al., 2016). TNFα expression can induce 
reactive oxygen species generation via mitochondria and through activation of NADPH oxidase 
(Morgan, 2010). Mitochondrial damage and generation of reactive oxygen species can stimulate 
the release of various cytokines including TNFα (Mittal et al., 2014). These changes in TNFα 
expression and secretion can modulate various parts of the cellular antioxidant system and 
directly increase the production of mitochondrial reactive oxygen species through damage to the 
electron transport chain (Mittal et al., 2014). In experiments involving exposing HK-2 cells to 
toxicants and/or ischemic injury, TNFα levels rose along with many other markers of toxicity, 
including increases in oxidative stress via dysfunction of cellular antioxidant systems, activation 
of an inflammatory response and associated proteins, and induction of programmed cell death 
(Gong et al., 2015; Zager et al., 2007; Zhang et al., 2013). 
 We examined TNFα as a potential indicator of oxidative stress. Our study showed that 
TNFα was released into the media at 72 h, while tissue showed a decline in expression at 48 and 
72 h (Figure 9, Chapter 2). Because TNFα expression was unaltered at 24 h (Figure 9, Chapter 2) 
it is unlikely that activation of inflammatory response is the cause of the oxidative stress 
observed. The decline in TNFα in the cells is consistent with loss from cells into the media; 
TNFα released into the media may contribute to greater oxidative stress. 
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TFV Alters Mitochondrial Function in HK-2 Cells  
The renal proximal tubular epithelial cell has a high requirement for ATP generation to 
maintain normal cellular processes such as active transport. The decline in cellular ATP levels 
caused by TFV would impair normal proximal tubular epithelial cell function.  In our initial 
study, we determined that TFV greatly diminished ATP levels following 72 h exposure but not at 
24 or 48 h exposure (Figure 6, Chapter 2).  Loss in cellular ATP was also seen in our subsequent 
studies using Seahorse XFp; ATP production was not altered at 24 or 48 h TFV exposure, but 
was diminished at 72 h (Figure 20, 21, and 22, Chapter 3).  While what is causing this loss in 
ATP production remains unclear, it may be due to several factors. Cytochrome c is a key 
component of the electron transport chain; cytochrome c mitochondrial leakage into the cytosol 
may contribute to the observed loss in ATP.   
TFV appears to directly alter the electron transport chain, which may also contribute to 
loss of cellular ATP.  At 24 and 48 h TFV exposure, maximal OCR is lower relative to control 
but basal OCR is unaffected (Figure 17, Figure 18, Chapter 3) when measured using Seahorse 
XFp technology.  ECAR is not affected at either time point.  However at 72 h TFV exposure, 
basal OCR and ECAR, and maximal OCR and ECAR are lower relative to control.  Upon further 
investigation in the mitochondrial stress test, 72 h TFV exposure results in lower ATP 
production, but does not affect spare capacity.  The results of our study suggest that TFV induces 
mitochondrial changes similar to other mitochondrial toxicants.   
One study using hepatocellular carcinoma cells to evaluate 27 compounds found that 
seahorse technology can be helpful in mitochondrial mechanistic studies.  Compounds such as 
rotenone, a known complex I inhibitor, show a decrease in OCR and spare capacity, but an 
increase in ECAR.  ATP synthase inhibitors such as oligomycin, show a decrease in OCR with 
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no effect on reserve capacity, while uncouplers such as 2,4-dinitrophenol increase OCR and 
ECAR with no effect on reserve capacity (Eakins et al., 2016).  These extracellular flux assays 
were able to correctly predict the mechanisms of mitochondrial toxicity in 76% percent of known 
test compounds used.  As TFV reduces OCR but does not alter spare capacity, it is possible that 
TFV inhibits ATP synthase activity.  Our studies indicated that ATP synthase expression was not 
diminished by TFV.  It is unlikely that loss of ATP synthase from the mitochondrial membrane 
contributes to the observed reduction in cellular ATP following TFV exposure. 
TFV Causes Multiple Mechanisms of Cell Death 
 Our study shows a loss of cell viability following TFV exposure within 24-48 h via 
necrosis.  However, markers of apoptosis are not observed until 72 h exposure.  Release of 
cytochrome c to the cytosol induces apoptosis via binding to Apoptotic protease activating factor 
1 (Apaf-1) to form an apoptotic complex that activates caspase 9 and eventually caspase 3 (Jiang 
& Wang, 2000; Liu et al., 1996).  Following 72 h exposure to TFV, there is observable release of 
cytochrome c into the cytosolic subcellular fraction as well as cleavage of caspase 3 and 9.  
These results are indicative that TFV causes mitochondrial damage that initiates apoptosis.   
 When cells undergo necrosis, organelles swell and break down, leading to disruption of 
plasma membrane integrity (Challa & Chan, 2010; Moquin & Chan, 2010; Schweichel & 
Merker, 1973).  This loss in membrane integrity leads to the release of intracellular contents. 
LDH is a stable enzyme that is expressed in every cell type; it is commonly used as a marker of 
necrosis (Burd & Usategui-Gomez, 1973; Chan et al., 2013).  Our study showed an increase in 
LDH release from HK-2 cells into the media following 24 and 48 h exposure (Figure 13, Chapter 
3), indicating that TFV induces necrosis in HK-2 cells within 24 h exposure.  These findings are 
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in line with clinical data of patients with TDF induced renal injury, which show marked tubular 
necrosis (Herlitz et al., 2010).  
Antioxidant Pretreatment Prevents TFV Cytotoxicity  
Resveratrol and ascorbic acid are widely known as antioxidants and have been shown to 
prevent renal toxicity of a number of chemotherapeutic agents that induce oxidative stress in 
vitro and in vivo rodent models, including cisplatin and cadmium (Do Amaral et al., 2008; Fu et 
al., 2017; Koyuturk et al., 2007; Maliakel et al., 2008; Valentovic et al., 2014).  N-acetyl-L-
cysteine (NAC) is the precursor to glutathione (GSH), an important cellular antioxidant.  NAC is 
most notably used to treat acetaminophen overdose by providing cysteine for glutathione 
synthesis to mitigate hepatic toxicity, but has been shown to protect hepatocytes from oxidative 
damage induced by cadmium and mercury in rats (Joshi et al., 2014; Wang et al., 2014). 
  Our study shows that a one h pretreatment with resveratrol, NAC, or ascorbic acid 
protects HK-2 cell viability when exposed for 24 h to 3 or 14.5 μM TFV (Figure 6, Chapter 2).  
It should be noted that high concentrations of NAC (0.5-1 mM) were required to induce a 
protective effect; resveratrol may be the best choice in prevention of TFV induced cytotoxicity as 
it required the lowest concentration to induce a protective effect (5 μM).  It is unclear by what 
mechanism antioxidants protect against TFV toxicity. Our studies did not show markers of 
oxidative damage (protein carbonylation and 4-HNE adduct formation) until 72 h exposure, but 
protection was observed within 24 h TFV exposure.   
Conclusions  
 My dissertation research over the last four years has led to a general understanding of the 
mechanism of TFV induced cytotoxicity.  This mechanistic understanding is essential if clinical 
methods of prevention are to be developed.  We have determined that upon entry into the 
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proximal tubule cell, TFV causes necrotic cell death within 24- 48 h.  TFV enters the 
mitochondria and causes oxidative stress, leading to increased protein carbonylation, a loss of 
cellular ATP production, lipid peroxidation, and a loss of mitochondrial membrane integrity.  
This loss of membrane integrity leads to leakage of cytochrome c and MnSOD to the cytosol, 
where cytochrome c activates caspase 9 and 3, leading to apoptotic cell death within 72 h 
exposure (Figure 27).  Although multiple mechanisms of cell death appear to be involved, 
pretreatment with NAC, ascorbic acid, or resveratrol protected against TFV cytotoxicity within 
24 h.  Resveratrol showed the most effective protection, and warrants further study into possible 
clinical prevention of TFV induced nephrotoxicity.   
Future Directions  
 My study was the first to investigate the mechanism of TFV induced cytotoxicity in 
depth.  While it has answered many questions, there are several left unanswered.  It remains 
unknown what causes the observed loss in cellular respiration and ATP levels; while inhibition 
of ATP synthase may play a role, more work needs to be done to determine whether TFV 
directly alters function of electron transport enzymes.  Additionally, what triggers necrotic cell 
death at lower exposure time points is unknown at this time.  This alternate mechanism of 
toxicity may play a role in the observed antioxidant protection at 24 h TFV exposure.  Additional 
research needs to be conducted to determine what mechanism triggers necrotic cell death, how 
antioxidants prevent this, and if antioxidants are also effective at longer treatment periods.       
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Figure 27. Summary of TFV induced cytotoxicity.  TFV enters the proximal tubule cell via 
OAT 1/3 transporters.  TFV induces necrotic cell death by an unknown mechanism.  TFV enters 
the mitochondria and reduces cellular respiration and ATP levels, causes oxidative stress and 
mitochondrial damage.  Mitochondrial damage leads to the release of MnSOD, cytochrome c, 
and TNFα.  Cytochrome c release activates caspase 9 and 3, leading to apoptotic cell death. 
Necrotic cell death can be prevented with antioxidant pretreatment.    
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APPENDIX B:  LIST OF ABBREVIATIONS 
4-HNE….4-hydroxynonenal 
ADP….adenosine diphosphate 
AIDS….Acquired Immunodeficiency Syndrome 
Apaf-1….Apoptotic protease activating factor 1 
ART….antiretroviral therapy 
Asc….ascorbic acid 
ATCC….American Type Culture Collection 
ATP….adenosine triphosphate 
AUC….area under the curve 
BSA….bovine serum albumin 
BMD….bone mineral density 
BUN….blood urea nitrogen 
CI….confidence interval 
COBI….cobicistat 
COX-IV….cytochrome c oxidase IV 
CYP….cytochrome P450 
DMSO….dimethylsulfoxide 
DNPH….dinitrophenylhydrazine 
EC50….effective concentration in 50% of population 
ECAR….extracellular acidification rate 
EFV….efavirenz 
EVG….elvitegravir 
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FCCP….carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone 
FDA….Food and Drug Administration 
FSGS….focal segmental glomerulosclerosis 
FTC….emtricitabine 
GFR….glomerular filtration rate 
GSH….glutathione  
HAART….highly active antiretroviral therapy 
HBV….hepatitis B 
HIV….human immunodeficiency virus 
HIVAN….HIV-associated nephropathy 
HK-2….human kidney 2  
HRP….horse radish peroxidase 
LDH….lactate dehydrogenase 
LPV….lopinavir 
MDCKII….Madin-Darby canine kidney II 
MnSOD….manganese superoxide dismutase 
MtCO-1….mitochondrial-encoded cytochrome c oxidase subunit  
MRP1….multidrug resistance-associated protein 1 
MRP2….multidrug resistance-associated protein 2 
MRP3….multidrug resistance-associated protein 3 
MRP4….multidrug resistance-associated protein 4 
MtDNA….mitochondrial DNA 
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MTT….3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide  
NAC….N-acetyl-L-cysteine  
NADPH….nicotinamide adenine dinucleotide phosphate  
OAT1….organic anion transporter 1 
OAT3….organic anion transporter 3 
OCP….oral contraceptive pills 
OCR….oxygen consumption rate  
PBMCs….peripheral blood mononuclear cells 
PBS….phosphate buffered saline 
Pgp….P glycoprotein  
PrEP….pre-exposure chemoprophylaxis 
Res….resveratrol 
RNS….reactive nitrogen species 
ROS….reactive oxygen species  
RPV….rilpivirine 
RTV….ritonavir 
SQV….saquinavir 
TAF….tenofovir alafenamide 
TBST….tris buffered saline plus Tween 20  
TDF….tenofovir disoproxil fumarate  
TDP….tenofovir diphosphate  
TFV….tenofovir  
TMB….3,3t,5,5t-tetramethylbenzidine 
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TNFα….tumor necrosis factor alpha  
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and execution of educational regional conference involving several 
universities with over 100 attendees.  Sat on planning committee 
for the same conference in 2015.   
2015 – Present  American Medical Writers Association, Member  
2015 – Present  Text and Academic Authors Association, Member 
2015 -  Present   American Society for Pharmacology and Experimental  
Therapeutics, Member 
2014 – Present   American Association for the Advancement of Science, Member  
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2014 – Present   Society for Experimental Biology and Medicine, Member  
2013 - Present   Marshall University School of Medicine Graduate Student  
Organization  
 President:  May 2015 – April 2016  
 Historian:  May 2014 – April 2015  
 Member:  July 2013 – Present  
 
Community Service  
2016 – Present   Volunteer, Huntington City Mission, Huntington, WV 
2016 – Present   Volunteer, Veteran Administration Hospital, Huntington, WV 
December 2015   Coordinator, Jared Box Toy Drive for In-Patient Children,  
Huntington WV 
October 2013   Proctorville High School Science Fair Judge  
   
 
 
